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Numerous proteases are known to be necessary for cancer development and progression 
including Matrix Metalloproteinases (MMPs), Tissue Serine Proteases, and Cathepsins.  The 
goal of this research is to develop a Fe/Fe3O4 nanoparticle-based system for clinical diagnostics, 
which has the potential to measure the activity of cancer-associated proteases in biospecimens. 
Our nanoparticle-based “light switches” for measuring protease activity, consist of fluorescent 
cyanine dyes which are directly attached to Fe/Fe3O4 nanoparticles and porphyrins that are 
attached to Fe/Fe3O4 nanoparticles via consensus sequences.  
The consensus (cleavage) sequences can be cleaved in the presence of the correct 
protease, thus releasing a fluorescent dye from the Fe/Fe3O4 nanoparticle resulting in highly 




 for 12 proteases), selective, and fast nanoplatforms (required 
time: 60 min.). Upon escape, the emission intensity of the organic dye will significantly increase, 
which can be detected using fluorescence spectroscopy.  
In order to demonstrate the potential of this new technology of early recognition of 
various cancers several analysis types have been used. Blood and urine samples from human 
cancer patients and healthy volunteers, tissue and blood serum samples from human cancer 
patients, and canine urine and blood serum samples are some of those types.  
Blood samples from human cancer patients and healthy volunteers were used to 
demonstrate the potential of this new technology for the early recognition of breast and lung 
cancers. We were able to establish several proteases with diagnostic potential for breast cancer 
and non-small cell lung cancer. It is very likely that different cancers will feature different 
“protease signatures”, meaning that different proteases will be activated, depending on the origin 
of cancer. This permits the diagnosis of various solid tumors at different stages.  
Tissue samples were collected from normal tissues, from the boundary of the tumor and 
from the tumor of the same person. Performed fluorescence experiments clearly indicate that 
tissue samples from the tumor show the highest fluorescence indicating the highest concentration 
of the protease. Results can be used excellently in a diagnostic system for breast cancer. Based 
on our results measuring protease signatures offers an inexpensive and fast approach towards 
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Chapter 1 - Introduction 
 1.1 Cancer 
Diseases in which abnormal cells divide without control and are able to invade other 
tissues are known as cancer. Blood and lymph systems are the chief vectors in spreading cancer.
1
 
The causes for cancer can be divided into two major divisions: external factors and internal 
factors. Tobacco, infectious organisms, chemicals, and radiation are so-called external factors. 
Inherited mutations, hormones, immune conditions, and spontaneous mutations that occur from 
metabolism are so-called internal factors.
2 
Cancer is a major cause of death in the world, 
especially in USA, where it is the second major cause of death. In 2013, about 1,660,290 new 
cancer cases were diagnosed and about 580,350 Americans have died of cancer.
2
  
There is a variety of treatment methods available in order to treat cancer.  Most common 
methods are surgery, radiation, chemotherapy, hormone therapy and biological therapy. Before 
any treatment of cancer can be attempted, a correct diagnosis has to be performed. Therefore, 
developing robust methods for diagnosing cancer in the earliest disease stages is the key to 
overcoming this often fatal disease. The early cancer detection methods are so important, 
because the cancer survival rates can be significantly increased if it is detected at an early stage. 
The process of checking people for cancer, who do not have any symptoms of cancer, is 
commonly referred to as “screening”.
3
 Screening and detection methods differ from one type of 
cancer to the other, because there are significant biochemical differences between the types of 
cancer (e.g. brain, breast, lung, pancreas, prostate etc.). Most of these differences arise, because 
different types of cancer develop from different types of cells.  
This research is mainly focused on considers two main types of cancer, namely breast 
cancer and lung cancer. Consequently, the diagnostics of breast and lung cancer will be 
discussed. 
 1.1.1 Breast Cancer  
Other than skin cancer, breast cancer is the most widespread cancer type in women.
2 
 In 
the USA breast cancer shows the highest incidence rate. The lifetime probability of developing 
cancer for women is also high with breast cancer comparative to other cancer types. These facts 
warrant the importance of breast cancer detection: The 5-year relative survival decreases to 24 
   2 
 




There are several stages of breast cancer. The pathological classification of tumors that 
exist today is mainly based on changes in cell morphology. Early stage or stage 0 breast cancer is 
when the disease is localized to the breast with no evidence of spreading to the lymph nodes 
(carcinoma in situ).
1 
Stage 1 breast cancers are two centimeters or less in size and it has not 
spread any further. Stage 2 again can be divided into two categories.
1 
Stage 2A breast cancer is a 
tumor less than two centimeters across with lymph node involvement, or a tumor that is larger 
than two (but less than five) centimeters across without underarm lymph node involvement.
1
 
Stage 2B is a tumor that is greater than five centimeters across without lymph node involvement, 
or a tumor that is larger than two but less than five centimeters across with lymph node 
involvement.
1  
Locally advanced breast cancer (metastatic) results after cancer cells spread to the 
lymph nodes. Stage 3 can be divided in to three key parts. Stage 3A breast cancer is also called 
locally advanced breast cancer.
1
 The tumor is larger than five centimeters and has spread to the 
lymph nodes under the arm, or a tumor that is any size with involvement of 4-9 axillary lymph 
nodes.
1  
Stage 3B breast cancer is a tumor of any size that has spread to the skin, chest wall, or 
internal mammary lymph nodes (located beneath the breast and inside the chest). Inflammatory 
breast cancer falls into this category.
1
 Stage 3C breast cancer is a tumor of any size that has 
spread to more than 10 axillary lymph nodes. The Final stage is Stage 4 breast cancer. It is 
defined as a tumor, regardless of size, that has spread to places far away from the breast, such as 
bones, lungs, liver, brain, or distant lymph nodes.
1 
          
There is another approach to define the types of breast cancer, depending on the 
expression of receptors in the cell walls of the cancer cells. Endocrine receptors (estrogen or 
progesterone receptor) target hormones. ER+ means, the tumor expresses receptors for estrogen. 
PR+ means, it has receptors for progesterone. ER- and PR- mean that the tumor does not express 
receptors for either hormone. In general, hormone receptors promote tumor growth if they bind 
their targets. Roughly, two out of three of all breast cancer tests are positive for hormone receptors. 
HER2/neu (human epidermal growth factor receptor 2), also called ErbB2, is a protein 
that appears on the surface of some breast cancer cells. HER2 positive cancers express receptors 
for human epidermal growth factor. 
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All remaining tumors are grouped together and classified as “Triple Negative breast 
cancers”. That means, these cancers are not positive for estrogen, progesterone, or HER2 
receptors. It is noteworthy that the group of Triple Negative breast cancers is by no means 
homogeneous. 
On the other hand, the fourth group, “Triple Positive breast cancer”, is positive for 
estrogen receptors, progesterone and HER2 receptors.  
Depending on this classification, physicians obtain important information with regard to 
cancer treatment. For instance, the various sub-groups of breast cancers are known to react 
differently to combinations of anticancer drugs. The exception of this rule is again the group of 
Triple Negative breast cancers, which is very heterogeneous.
4
                                                                        
To date, there are several breast cancer detection methods available. The most important 
are mammography, ultrasound detection, magnetic resonance imaging and molecular breast 
imaging.
5
 Regarding the early detection of breast cancer, the American cancer society suggests 
following several screening guidelines.
1
 Firstly, starting at age 40, yearly mammograms are 
recommended. Secondly, as a part of the periodic health examination, a clinical breast exam 
should be included. Thirdly, women at the beginning in their early 20s should be told about the 
benefits and limitations of breast self exams. 
Figure 1.1 shows survival of breast cancer patients vs. stage of detection. According to 
Figure 1.1 breast cancer mortality can be substantially reduced if we can detect breast cancer at 
the localized stage, before it has metastasized.            
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Figure 1.1 : Survival of Breast Cancer Patients vs. Stage of Detection (Taken from : West 




 1.1.2 Lung Cancer 
 In both men and women, lung cancer causes more deaths than any other cancer. The 5-
year relative survival decreases to 4 percent at the distant stage, from 25 percent at the regional 
stage and 52 percent at the localized stage.
1
  
 There are three main factors, which decide the stage of the lung cancer. They are the size, 
how deep the tumor has invaded nearby tissue, and whether the cancer cells have spread to 
lymph nodes.
1
 Two major types of lung cancer are non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC).
1
  
 There are five stages of non-small cell lung cancer. Stage 0, abnormal cells are found 
only in the innermost lining of the lung.
1 
Stage 1, the tumor has grown through the innermost 
lining of the lung into deeper lung tissue and it is no more than 5 cm across.
1
 Stage 2, the tumor 
is smaller than 7 cm across and cancer cells are found in nearby lymph nodes.
1
 Stage 3, the 
   5 
 
tumor may be any size and more than one malignant tumor may be found within the lung.
1
 Stage 
4, malignant tumors are found in both lungs or the cancer has spread to other parts of the body.
1
  
 There are two stages of small cell lung cancer. The first stage is limited stage. Cancer is 
found only on one side of the chest.
1
 The second stage is called the extensive stage. Cancer is 
found in the lung and also in tissues on both sides of the chest or found in distant organs.
1
  
 There are several screening methods available for lung cancer. Some of them are tests of 




 1.2 Proteases  
Proteases are a class of enzymes that catalyze the cleavage of a specific peptide bond in 
other proteins. They are also called proteolytic enzymes or proteinases.
7
 There are six different 
catalytic classes of proteases named as aspartic, metallo-, cysteine, serine, threonine and 
glutamic. This classification is based on the group performing the nucleophilic attack at the 
carbonyl group. The nucleophile differs from one group to the other. Aspartic, metallo- and 
glutamic proteases have a polarized water molecule as the nucleophile within their active center. 
Serine and threonine proteases have the hydroxyl group and cysteine proteases have the  
sulfhydryl group as the nucleophile at the active center.
8
  
Cancer-related proteases have the potential to become reliable biomarkers for the 
detection of solid tumors in early stages.
9,10,11
 Quite a few proteases are known to be necessary 
for cancer development and progression including Matrix Metallo-proteinases (MMPs), 
urokinase plasminogen activator (uPA) and  Cathepsins (CTSs).
9,10,11
 They are critical cofactors 
during cancer progression. There are several remodeling processes that take place with the 
stroma, the ECM (Extra Cellular Matrix) and cell surfaces. Those processes are the requirements 
of the tumorigenic processes for the neoplastic, vascular or inflammatory cells invasion.  These 
proteases are expressed with tumor progression and metastasis. Also they cooperate with ECM 
and cell surface substrates. They do activate inactive zymogens, which are initially secreted as 





These proteases don't function individually. They do act in a cascade-like manner. Figure 
1.3 shows this network structure of the activity of proteases.
14,15
 Also these proteases are very 
stable in tissue and blood serum. Therefore, they are suitable biomarkers.
16
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 1.2.1 Serine Proteases 
“Serine proteases are members of the protease family. These enzymes are named after the 
reactive serine residue located in the active site that is essential for the function of the enzyme.”
17
 
Among those serine proteases, urokinase plasminogen activator (uPA) is playing a major role in 
association with cancer. It is involved in the processes of ECMdegradation and basement 




There are four main components of the uPA/uPAR system such as serine protease uPA, 
its cell membrane associated receptor (uPAR), a substrate (plasminogen) and plasminogen 




Figure 1.2: Involvement of Proteases with Cancer Development, With Permission of 
Reference 13 
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Figure 1.3: Intersecting Protease Pathways during Neoplastic Progression, With 
Permission of Reference 13 
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In order to get the uPA enzyme active, several processes should be followed. The 
zymogen plasminogen can be transferred to the active serine protease plasmin by the active uPA 
enzyme. This active serine protease plasmin engages in supporting tumor migration by means of 
direct proteolytic digestion or activation of other zymogen proteases. The active uPA enzyme is 
an active two-chain uPA molecule. It is formed upon the cleavage of bound pro-uPA and uPAR 
system by various proteases. Pro-uPA is a zymogen, which is deficient in plasminogen activating 
activity. So uPA is produced and secreted as single chain polypeptide, pro-uPA.
20
 
 1.2.2 Matrix Metalloproteinases 
“Matrix metalloproteinases (MMPs) constitute a family of extracellular matrix (ECM) 
remodeling proteinases implicated in physiological and pathological processes that include 
morphogenesis, wound healing, tissue repair and the progression of diseases such as arthritis, 
cancer and cardiovascular disease.”
8
 They can be sub classified according to substrate specificity 
(e.g. collagenases, gelatinases, stromelysins). They need a zinc (II) cation at the active site. This 
family consists of about 20 enzymes.
21
 There are at least three conserved regions with these 
MMPs. Proteolytic activity is performed by the zinc binding motif (HEXXHXXGXXH), 
interaction with the zinc ion in the zymogen form is achieved by the cysteine residue of the 
propeptide cysteine site (PRCGXPD) and maintenance of the zinc binding site integrity is done 
by the methionine turn (XXMXP).
22
 Tumor angiogenesis is the key step in which MMPs are 
involved, especially MMP2 and MT1-MMP that are expressed by endothelial cells.
21  
Hormones, 
growth factors, cytokines and tissue inhibitors of metalloproteinases (TIMPs) are the regulatory 
factors of the expression of most MMPs. Table 1.1
23
 shows the categorization of the MMP 
family and Table 1.2
22
 shows implication of MMPs in cancer progression. Figure 1.4 shows how 
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Structural Class Common Name(s) 
MMP-1 Simple hemopexin domain 
Collagenase-1, interstitial collagenase, fibroblast 
collagenase, tissue collagenase 
MMP-2 Gelatin-binding 
Gelatinase A, 72-kDa gelatinase, 72-kDa type IV 
collagenase, neutrophil gelatinase 
MMP-3 Simple hemopexin domain 











Simple hemopexin domain 
 
Collagenase-2, neutrophil collagenase, PMN 





















Simple hemopexin domain 
 












MMP-15 Transmembrane MT2-MMP, MT-MMP2 














Simple hemopexin domain 
 
















Homologue of Xenopus XMMP 
MMP-22 
 
Simple hemopexin domain 
 






Cysteine array MMP (CA-MMP), femalysin, 
MIFR, 
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Table 1.2 : Implication of MMPs in Cancer Progression,  Taken from Reference 22 
 
 
Sources of MMPs 
 Tumor cells 
 Myoepithelial cells 
 Endothelial cells 
 Perivascular cells (pericytes, smooth 
muscle cells) 
 Inflammatory cells (neutrophils, 
macrophages, mast cells) 
 Fibroblasts (myofibroblasts) 
 
 
1 - Epithelial to mesenchymal transition 
- Loss of cell-cell adhesion:  
  E-cadherin cleavage 
- Release of β-catenin and transcriptional 
  regulation of gene expression      
2 - Proliferation, apoptosis 
- Activation of growth factors 
- Release of growth factors from bound 
  protein or ECM 
- Shedding of cell surface receptor (FGF-R1) 
- Shedding of FasL, TNFa 
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3 -  Angiogenesis 
- Activation of angiogenic factors 
- Release of angiogenic factors from bound 
  protein or ECM 
- Activation of integrin subunits 
- Generation of angiogenic inhibitors 
  (angiostatin, tumstatin, endostatin) 
- Recruitment of perivascular cells 
- Endothelial cell tubulogenesis 
4 - Migration, invasion, metastases 
- ECM degradation 
- Exposition of cryptic site by proteolysis 
- Shedding of cell surface molecules  
  (CD44, tTG) 






Figure 1.4 : General Paradigm for the Expression of Proteases during Cancer Progression, 














MMP 1 - Collagenase 1 
MMP 3 – Stromolysin 1 
MMP 7 – Matrilysin 
MMP 11 – Stromolysin 3 




MMP 3 – Stromolysin 1 




MMP 1 - Collagenase 1 
MMP 2 – Gelatinase 1 
MMP 3 – Stromolysin 1 
MMP 7 – Matrilysin 
MMP 8 - Collagenase 2 
MMP 9 - Gelatinase 2  
MMP 11 – Stromolysin 3 
MMP 13 – Collagenase 3 
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 1.2.3 Cathepsins 
Cathepsins are a group of lysosomal cysteine proteases belong to the papain family. 
Cathepsins B, C, H, F, K, L, O, S, V, W and X (sometimes called cathepsin Z) are the 11 
members of human Cathepsins and there are 18 members found in mice. The active site of these 
cathepsins consists of cysteine, histidine and asparagine residues. Table 1.3 shows the 




Table 1.3 : Nomenclature and Expression Patterns of Cysteine Cathepsins in Human and 
Mouse ( Taken from Reference 25) 
Protease (Alternative names) Human (11) Mouse (18) Expression Pattern 
Cathepsin B CTSB CtsB Ubiquitous 
Cathepsin C 
(J, Dipeptidyl peptidase I) 
CTSC CtsC Ubiquitous 
Cathepsin F CTSF CtsF Ubiquitous 
Cathepsin H CTSH CtsH Ubiquitous 




Cathepsin L CTSL - Ubiquitous 
Cathepsin L2 (V) CTSL2 CtsL 
Thymus, testis, cornea, 
epidermis, 
macrophages 
Cathepsin O CTSO CtsO Ubiquitous 
Cathepsin S CTSS CtsS 
Lymphatic tissues, 
antigen -presenting 




Natural killer (NK) 
cells, cytotoxic T 
lymphocytes 
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Cathepsin X (Z, P, Y) CTSZ CtsZ Ubiquitous 
Cathepsin J - CtsJ Placenta 
Cathepsin M - CtsM Placenta 
Cathepsin Q - CtsQ Placenta 
Cathepsin R - CtsR Placenta 
Cathepsin 1 - Cts1 Placenta 
Cathepsin 2 - Cts2 Placenta 
Cathepsin 3 - Cts3 Placenta 
Cathepsin 6 - Cts6 Placenta 
 




Figure 1.5: Overexpression and Secretion of Cathepsins Induce the Invasion and 
Metastasis of Tumor Cells, From Reference 26   
 
Normal  cells 
Tumor cells 
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“Cathepsins B, L and D are lysosomal cysteine and aspartic proteinases, distributed in 
almost all mammalian cells.”
26
 Basically all cathepsins are involved in cancer progression. 
Degradation of the extracellular matrix is the major activity of cathepsin L.
26
 Cathepsin B 
promotes cancer cell in invasion via matrix degradation. Reduction of the primary immune 
response is the important activity of cathepsin D.
26
   
Figure 1.5 shows the imbalance between cathepsins and CPIs, cathepsin protease 
inhibitors in tumor cells.
26
  
 1.3 Proteases and Breast Cancer 
Several proteases from the above three families are specifically involved in the 
progression of breast cancer.  
First, from the MMPs family, Iwata et al. have shown MMP 1, MMP 2 and MMP 9 are 
highly expressed in human breast carcinoma cells.
27
 Kossakowska et al. and other researchers 
have shown that in addition to MMPs 1, 2 and 9, MMPs 3, 11, 13 and 16 also have a high 





from the family of serine proteases, urokinase plasminogen activator (uPA) is the 
key member, which is involved in the progression of breast cancer. 
28,29  
Third, we have to consider the cathepsin family. Estrogen has an effect on breast cancer 
growth and invasion. That effect can be mediated by cathepsin D, because it can work as an 
autocrine mitogen that can be activated at acidic pH, which will lead to the degradation of the 
extracelluar matrix.
30
 Also cathepsin B can degrade type IV collagen, which will lead to the 
invasion by inflammatory breast cancer cells.
31 
 1.4 Proteases and Lung cancer 
There are several proteases engaged in lung cancer. Most of them belong to any of the 
three protease families discussed in 1.2. 
Starting with the MMP family, Muller et al. reported the overexpression of some MMPs 
with the NSCLC. They showed overexpression of stromelysin-2 (MMP 10), collagenase-1 
(MMP 1), and pump-1 (matrilysin, or MMP 7) messenger RNA in human non-small cell lung 
cancer (NSCLC) tissues.
32
 The levels are high compared to normal bronchial mucosa. Also 
Compared to normal tissue stromelysin-3 (MMP 11), collagenase-1 (MMP 1), gelatinase B 
(MMP 9), and matrilysin (MMP 7) are significantly higher in lung tumors.
31
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Urokinase - type plasminogen activator (uPA) and its receptor (uPAR) also play a major 
role in lung cancer metastasis.
33
 
With regard to the cathepsin family, tumor progression is accelerated by overexpression 
of cathepsin B.
34
  Cathepsin L is another enzyme from the cathepsins family, which is elevated 
in lung tumor tissue. Cathepsin S is elevated in non-infiltrated and infiltrated lymph nodes.
35
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 1.5 Nanoparticle based “Light Switches” 
 1.5.1 Motivation for the Development of a “Light Switch”  
Most of the studies in cancer diagnostics have been performed using ELISA (enzyme 
linked immunosorbent assays).
37
 It is impossible to determine the activity of the proteases when 
the concentration of them is measured using ELISA. The reason behind that is, these proteases 
occur as inactive precursors (zymogens), active enzymes or enzyme inhibitor complexes. They 
are activated through an activation network. The activation network for MMPs is shown in 
Figure 1.6.  
 
Figure 1.6 : Expression of Distinct Matrix Metalloproteinases (MMP’s) by Tumor Cells, 
Stromal Fibroblasts (FB), and Inflammatory Cells (PMN, polymorphonuclear leukocyte; 
MC, monocyte; LC, lymphocyte, scc: squamous cell carcinoma, (Taken from Reference 38)  
  
In Figure 1.6, the emphasis is on “carcinoma”. Activation of latent MMPs is indicated by 
“+”. MMP’s that have been measured in the research are marked in red. 
 Other than ELISA, there are several approaches towards cancer diagnostics. Some of 
them are electrochemical analysis methods
39
, immunohistochemical staining methods
40
 and 
fluorescence in situ hybridization (FISH).
41
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 Unfortunately, cancer does not show significant symptoms in early stages. Consequently, 
the detection of cancer at stages where treatment is feasible with established technologies, is very 
challenging. If we can identify cancer by performing a blood test of a person, that would be a 
significantly early cancer detection method. This should be done during the annual checkup of a 
person. My thesis research is based on the paradigm that monitoring the protease signature of the 
patient provides the basic concept for early cancer detection and detecting cancer recurrence. 
This is, principally, the motivation behind developing nanoplatforms for cancer detection based 
on the “nanoparticle based light switch” technology.  
I have used fluorescence detection for the quantitative monitoring of active proteases (not 
zymogens!) using highly protease-selective nanoplatforms. Fluorescence detection methods have 




 Based on the literature quote above, I have tested 12 proteases using this nanoparticle - 
based system (Light switch). Table 1.4 shows the proteases that were used and the consensus 
sequences for them.  
 
Table 1.4: Consensus Sequences of the Proteases
43,44
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Cathepsin B SLLKSR-MVPNFN 
Cathepsin D SLLIFR-SWANFN 
Cathepsin K GPR-AG 
Cathepsin L SGVVIA-TVIVIT 
 







 that feature consensus sequences (cleavage sequences) 
between a fluorescent dye and a quencher has been sparked by the pioneering research of R. 
Weissleder and collaborators.
48
 Consensus sequences are oligopeptides that are optimized to 
facilitate fast proteolytic cleavage by their respective protease, but not by every other protease. 
Therefore, they are characterized by a very high selectivity (by a factor of 40 to 1,000) towards 
the protease they are designed to detect.
44
 Influenced by N. J. Turro, who introduced the concept 
of a “molecular light switch” in 1990
49
, the research on in-vitro protease activity sensors during 
the last decade has been geared towards ever higher fluorescence signal enhancement upon 
cleavage of the consensus sequence between fluorophore and quencher.
50 
For in-vitro 
applications, near-infrared (NIR) dyes have been developed, which were optimized for maximal 
light penetration depth.
51
 Protease sensor based on fluorescence quenching by tethered 
nanoparticles
52
 or fluorescent quantum dots to which quenchers are tethered via consensus 
sequences
53
, were explored during the last decade. The established limit of detection of 
fluorescent protease sensors is in the low picomolar to sub-picomolar range.
54 
 
 1.5.2 Consensus-Sequence Based Fluorescence Detection of Protease Activity 
  In this work we have combined fluorescence resonance energy transfer quenching 
(FRET)
55
 and plasmon-resonance quenching
56 





 for a series of 12 cancer-related proteases. The resulting nanoplatforms are based 





 is tethered via consensus 
sequence to dopamine, which is bound to the Fe3O4 layer at the Fe/Fe3O4 surface. The dye 
cyanine 5.5
60
, which possesses overlapping absorption/fluorescence spectra with the 
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fluorescence spectrum of TCPP, was permanently attached via dopamine-anchors to the 
nanoparticle’s surface. 
The logic behind this light switch technology is that it can be switched “on” in the 
presence and activity of the enzyme. This process is as follows: A specific consensus sequence 
can be cleaved by its specific enzyme, which will lead to fluorescence of the attached 
fluorophore. Before we introduce the specific protease that is able to cleave the consensus 
sequence to the system, the fluorescence of the fluorophore is quenched. Quenching of TCPP-
fluorescence occurs via two pathways. The first is plasmonic quenching by the nanoparticle. 
61,62
 
The second is singlet to singlet energy transfer from TCPP to cyanine 5.5, also known as 
fluorescence resonance energy transfer (FRET).
61
 Both pathways are necessary to ensure 
significant quenching of TCPP as long as it is tethered to the Fe/Fe3O4-nanoparticle. After the 
introduction of the protease, it will cleave the consensus sequence and then the fluorophore is 
free to move away from the nanoplatform. Consequently, both quenching mechanisms become 
inefficient with increasing distance. 
 1.5.3 Technical Requirements for a Successful Nanoplatform for Early Cancer 
Diagnostics by Means of Fluorescence Detection 
Many state-of-the-art analytical methods, such as immunoassays
16
 or electrochemical 
detection methods
63,64
 can quantify the protease concentrations occurring in cancer tissue, but 
they are not (yet) sensitive enough to measure protease activities that are observed during early 
stages of cancer development. These tests have to be performed in blood (serum) to have any 
value in early diagnostics. This requirement leads to significant dilution effects. The 
development of nanoplatforms for the diagnostics of solid tumors, such as breast cancer or lung 
cancer, in early stages, is based on the paradigm that the concentration of each proteolytically 




 in the blood serum of healthy 
human subjects.
42
 It is anticipated that one or several proteases are overexpressed in early 









. The concentration of selected proteases will then further increase in late stage cancer 
patients.
42
 It is noteworthy that virtually all proteases are biosynthesized as zymogens (inactive 
precursor enzymes), which require enzymatic activation.
65
 Zymogens are usually not indicative 
of tumor progression.
65
 Therefore, it is of great importance to measure the activity, and not the 
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concentration, of cancer-related proteases.
42
 In stark contrast, immunoassays rely on the presence 




Figure 1.7 : Nanoplatform for Protease Detection.  
 
With this nanoplatfrom, which is shown in figure 1.7, one Fe/Fe3O4-nanoparticle is 
linked in average to 35+/-3 TCPP-molecules via consensus sequence (one type of sequence per 
nanoplatform) and 50+/-4 cyanine 5.5 molecules via amide linkages. 
 1.6 Fluorescence Detection 
Steady state fluorescence detection is the technique used during the analysis. This 
technique was selected due to its high sensitivity in detecting variations in the concentration of 
fluorophores.
66
 "Fluorescence is the property of some atoms and molecules to absorb light of a 
particular wavelength and after a brief interval, termed the fluorescence lifetime, to emit light at 
a longer wavelength."
67
 That means the luminescence occurs from one excited electronic singlet 
state to another singlet (usually the ground state). With fluorescence ∆s=0 processes are allowed 
and ∆s= 1 processes are forbidden. That means singlet-to-singlet energy transfer is spin allowed 
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Figure 1.8: Simplified Version of Jablonski Diagram (According to Reference 68) 
 
Figure 1.8 shows the resulting energy diagram.
68
 Electronic energy states are denoted as 
S. The Singlet ground state is S0, singlet first state is S1 and singlet second state is S2 etc. In each 
electronic energy state, there are several vibrational energy levels denoted as 0,1,2, etc. Upon 
light absorption a fluorophore is excited to a higher energy electronic state such as S1 or S2. Then 
the internal conversion occurs which means the fluorophore is relaxed back to the lowest 
vibrational level of S1. Then the emission from S1 to S0 is known as fluorescence.  
Figure 1.9 shows the schematic diagram of the spectrofluorometer.
68
 The quality of the 
parts of the spectrofluorometer is important for the accomplishment of accurate fluorescence 
measurements. 
   24 
 
 
Figure 1.9: Schematic Diagram of the Spectrofluorometer, with permission from Reference 
68 (PMT: Photomultiplier Tube)  
 
The two main types of fluorescence measurements are steady-state and time resolved 
fluorescence.
68
 Steady state measurements are the widespread type. Throughout my research,  
steady state fluorescence measurements are used. The fluorescence intensity is recorded upon 
illuminating the sample with a continuous light beam. 
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 1.6.1 Fluorophores 
A fluorescent molecule (usually a aromatic molecule), which can emit light upon 
excitation is a fluorophore. There are two major classes: Intrinsic and extrinsic fluorophores. 
Naturally, occurring fluorpohores are known as intrinsic fluorophores. Well-known intrinsic 
fluorophores are chlorophyll, NADH and flavins.  Extrinsic fluorophores are the ones, which 
have to be added to the sample to provide fluorescence. Well-known extrinsic fluorophores are 
fluorescein and rhodamine. In order to be used with a given application, the optical 
characteristics of the particular fluorophore should be considered.
68
 
 1.6.1.1 Porphyrins 
Porphyrins are naturally occurring organic compounds. The most important porphyrin is 
heme, which is the pigment in red blood cells. They are aromatic molecules. Porphyrins have a 
planar macrocyclic structure of four pyrrole rings connected by methine bridges.
69
  There are 
several applications of porphyrins. Main application with this research is the capability of acting 




 are few other 
applications of porphyrins. Porphyrins have a strong absorption in the 400-450 nm region (Soret 
band) and weaker absorptions in the 500-700 nm region (Q-bands).
72
 Among the porphyrins, we 
have selected the Tetrakis(4-carboxyphenyl)porphyrin (TCPP). Figure 1.10 shows the chemical 












Figure 1.10: Chemical Structure of Tetrakis(4-carboxyphenyl)porphyrin (TCPP) 
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), TCPP features two 
strong emission peaks at 650 nm and 716 nm in PBS buffer (phosphate buffered saline, pH = 
7.4).
74
 When tethered to Fe/Fe3O4-nanoparticles, the maximum of the Soret band is slightly red-
shifted to 421 nm, whereas its fluorescence maxima are slightly blue-shifted (647 and 707 nm). 
The TCPP emission spectrum has a total range from 620 nm to 740 nm. The UV-Vis spectrum of 
Cy 5.5 in PBS buffer reveals a broad absorption over the range of 550 nm to 745 nm with two 
maxima at 630 nm and 680 nm respectively (Figure 1.11).
75
 We have selected TCPP and cyanine 
5.5 because of their broad overlap between the emission spectrum of TCPP and the absorption 
and emission spectra of cyanine 5.5. Significant fluorescence quenching of TCPP by cyanine 5.5 
in PBS is observed.  
 
Figure 1.11: Normalized UV/Vis-Absorption and Fluorescence Spectra of TCPP and 
Cyanine 5.5 
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1.6.2 Fluorescence Quenchers 
There are several substances, which can act as fluorescence quenchers. Well known ones 
are molecular oxygen, heavy atoms and quenchers of protein fluorescence.
68 
 
 1.6.2.1 Quenching of Fluorescence 
A process that decreases the fluorescence intensity is known as fluorescence quenching. 
There are several factors, which determine the extent of quenching. They are the sort of 
interaction between the fluorophore and the quencher, energy of the emission of the fluorophore 
and the characteristics of the quencher. Here with this research plasmonic quenching by the 
nanoparticle and Fluorescence Resonance Energy Transfer (FRET) are the two main types of 
quenching mechanisms that should be addressed.   
 1.6.2.1.1 Plasmonic Quenching by Nanoparticles 
Optical properties of the nanoparticles play a main role with plasmonic quenching. "The 
surface plasmon resonance (SPR) is the absorption band resulting when the incident photon 
frequency is resonant with the collective oscillation of the conduction band electrons."
76
 Excited 
state fluorophore acts as an oscillating dipole. When the metal nanoparticle and the fluorophore 
are in close proximity several modifications can occur in that environment. One modification is 
the change in rate of emission of radiating energy. Another modification is the change in the 
electric field felt by the fluorophore due to the interaction of the incident light with the close by 
metal surface. This modified environment, which occurred due to the above explained 
interactions can increase or decrease the field felt by the fluorophore also it can increase or 
decrease the radiative decay. Based on that, fluorescence quantum yield or the fluorescence 
lifetime can be either increased or decreased. Therefore the fluorescence quenching or the 
fluorescence enhancement of the surface plasmon of the metal nanoparticle depends on the 
fluorophore used.
77,78 
 1.6.2.1.2 Fluorescence Resonance Energy Transfer (FRET) 
This has become a widely used tool in several applications with monitoring 
biomolecules.
79
 FRET between fluorescent proteins is a good example.
80
 FRET is a nonradiative 
process and an electrodynamic phenomenon. In here, the energy transfer occurs between a 
excited dye donor and a dye acceptor in the ground state through long-range dipole dipole 




 In FRET systems the major requirement is the spectral overlap of the donor 
emission and acceptor absorption. Figure 1.12 shows the schematic diagram of FRET process.
81
  
                              
FRET efficiency (E) is given by equation 1,
68
 where R0 is the forester distance at which 
the transfer efficiency E = 50%; R is the distance between the energy donor and acceptor. 
 
Figure 1.12: Schematic of the FRET Process between Donor and Acceptor, with permission 
from Reference 81 
(1) 
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 1.6.2.2. Stern - Volmer Plot 
Stern - Volmer plots are based on the Stern - Volmer equation. Equation 2 shows the 
Stern - Volmer equation. It is used to explain collisional quenching of fluorescence. Fluorophore 




In this equation F0 is the fluorescence in the absence of the quencher, F is the 
fluorescence in the presence of the quencher, kq is the bimolecular quenching constant , τ0 is the 
lifetime of the fluorophore and Q is the concentration of quencher. The Stern-Volmer quenching 
constant is given by KD = kq0. Stern - Volmer plots are used to analyze quenching data. The 
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 1.6.2.3. FRET of TCPP to Cyanine 5.5 at Fe/Fe3O4-Nanoparticles 
We have analyzed the FRET of TCPP to cyanine 5.5 at the surface of the Fe/Fe3O4-
nanoparticles by applying a mathematical model for the analysis of luminescence quenching at 
starburst dendrimers, which is described in detail in reference 
82
. Assuming that 1) both dyes are 
randomly distributed at the nanoparticles’ surface, and 2) that each TCPP can be quenched by 
more than one molecule of cyanine 5.5 and 3) that the cyanine 5.5 quenchers act independently 
of each other, the total intensity of TCPP can be described by equation 3. 
 
The variables used here are defined as follows: p, Poisson distribution, N, number of 
nanoparticles, n1, number of TCPP molecules, n2, number of cyanine 5.5 molecules, 1, average 
number of TCPP molecules that are attached to each nanoparticle; 2, average number of cyanine 
5.5 tethered per nanoparticle, R: radius of the Fe/Fe3O4-nanoparticle, L, energy transfer 
interaction range; and I, luminescence intensity. 
 
Figure 1.14: Diagram used for the Computation of the Attenuation Factor, Equation 5.  
The energy transfer distance s between TCPP and cyanine 5.5 is measured on the surface 
of the nanoparticle (heavy line). This is not to be confused with r, the shortest distance between 
both dyes. 
I0 is obtained by substituting 1 = 0: 
 
(4) 
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The attenuating factor  represents the quenching of a single photoexcited TCPP by all 
cyanine 5.5, which are tethered to the surface of the nanoparticle with radius R. Quenching will 
depend on the distance s measured along the surface of the nanoparticle (Figure 1.14). It is 
approximated to 1 - e
-s/L










For the largest consensus sequence (CTS L, R = 10.15 nm, I
0
/I = 3.73),  is 0.9254 and L 
(Förster radius) was calculated to 4.4 nm. CTS K is the smallest consensus sequence    (R = 8.7 
nm, I
0
/I = 1.79),  is 0.9684. For the smallest nanoplatform, L is 2.3 nm. Both, the upper and 
lower bound for L are well within the established FRET distances (1 to 6 nm).
55
 Note that the 
longer consensus sequences may “bend back”, decreasing the effective radius of the 
nanoplatform. Under these conditions, FRET is enhanced while TCPP is tethered to the 
nanoparticles, resulting in a larger luminescence increase when TCPP is cleaved off by its 
respective enzyme. 
 
 1.6.3. Cyanine Dyes 
Cyanine dyes are highly conjugated, fluorescent molecules. They have the absorption and 
emission wavelengths in the near red and infra-red region (600–900 nm). They are known as 
near infra red (NIR) fluorescent dyes. Cyanine dyes have been used in many fields of science, for 
instance as photosensitizers, phototherapeutic agents and studies of nucleic acids. Figure 1.10 
shows the general formula of the cyanine dye.
83
 Some other important features of cyanine dyes 












n= 0, 1,2, etc. 
X = S, O, NH, CRR' 
Figure 1.15: General Formula of the Cyanine Dye  
 
Symmetric Cyanine dyes consist of the same heteroaromatic components conjugated by a 
methine chain and asymmetric Cyanine dyes consist of two different heteroaromatic components 
conjugated by a methine chain.
86
  The number of the cyanine denotes the number of methine 
groups in the structure. There are several cyanine dyes having different absorption and emission 
bands; e.g.: (Cy-3.0 (λex=538, λem=560), Cy-5.0 (λex=639, λem=660), Cy-7.0 (λex=740, λem=760) 
and Cy-7.5 (λex=808, λem=830)) 
There are also some draw-backs of cyanine dyes, such as hydrophobicity and a strong 
tendency towards aggregation.  
Through out this research, biological samples such as urine, blood serum and tissue 
samples are analyzed.  In order to increase the sensitivity of these dyes, they should comprise of 
hydrophilic character. Since cyanine dyes have a highly conjugated Π system, they are 
hydrophobic in nature. So the dye should be structurally modified to introduce hydrophilic 
groups. Linking polar groups such as sulfonate (SO3
-
) is the best strategy to achieve this. It gives 
negative charge to the dye structure, making it more hydrophilic.
84,85
  
Aggregation of these dyes can result in low fluorescence intensities and blue-shifted 
absorption peak. In our assay model Cyanine 5.5 dye is attached to the iron/iron oxide 



















Figure 1.16: Chemical Structure of Cyanine 5.5 
 
Key features of Cyanine 5.5 are long wavelength absorption in the NIR region, large 
extinction coefficient, good solubility and minor tendency to self-aggregate, which make it one 
of the major contributors to the nanoplatform
87
 The reason behind choosing cyanine 5.5 as the 
fluorescence quencher is explained in section 1.6.2.1. 
 1.7 Iron/ Iron oxide Nanoparticles 
Nanoparticles are particles with sizes in the range of 1–100 nm, dispersed in gaseous, 
liquid or solid media. Nanoparticles are thermodynamically unstable. The major difference 
between nanoparticles and larger colloids or bulk materials is their very high surface area. Due to 
the small size of nanoparticles, they have unique optical, magnetic and chemical properties. Iron 
nanoparticles are attractive to work with because of their chemical and physical properties, 
among them their very soft magnetic nature, the second highest room temperature value for the 
saturation magnetization, σs, and low magnetocrystalline anisotropy.
88
  
The earliest method of producing iron nanoparticles is dispersing them in mercury. Lately 
organic solvent-based methodologies have been used in preparation. The reasons behind this 
change are the toxicity of mercury vapors and the relative ease of removing organic solvents.
89
  
There are several methods that are currently used in the synthesis of iron nanoparticles. 
One is thermal decomposition of iron pentacarbonyl. The major requirements of this method are 
iron pentacarbonyl, energy in the form of heat (or sonication), an appropriate surfactant/solvent 
system, and a means to remove the only by-product, carbon monoxide. Sonochemical 
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decomposition of iron pentacarbonyl is the second method.
90
 Iron carbonyl is decomposed due to 
the localized heat provided by the acoustic activation. The third method is the reduction of iron 
salts and oxides. The vapor phase method is the forth type for the synthesis of iron nanoparticles. 




There is a vast array of applications with iron nanoparticles. They can be used in 
magnetic and electrical applications. Also they can be used in catalytic applications. Biomedical 
applications, such as Magnetic Resonance Imaging (MRI) or magnetic hyperthermia are another 
very important application of iron nanoparticles.
91
 The key reason in using iron/iron oxide 
nanoparticles in this research is that they provide additional surface plasmonic quenching to the 
fluorophore. Also it serves as a platform to link the fluorophore via peptide sequence and the 


















   35 
 















 Taylor, P. Modelling the impact of changes in sensitivity on the outcomes of the UK breast 
screening programme, J. Med. Screen, 2010, 17, 31-36. 
7 Duffy, M. J. Proteases as Prognostic Markers in Cancer, Clin. Cancer Res. 1996, 2, 613-618. 
8
 Ugalde, A. P.; Ordonez, G. R.; Quiros, P. M.; Puente, X. S.; Lopez-Otin, C. Metalloproteases 
and the degradome, Methods Mol. Biol. 2010, 622, 3-29. 
9
Mandhare, M. N.; Patil, P. H.; Jagdale, D. M.; Kadam, V. J. Targeting matrix 
metalloproteinases: an important strategy in cancer therapeutics, Int. J. Pharm. Sci. Rev. Res. 
2012, 12, 27-39. 
10
Rabbani, S. A.; Xing, R. H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and 
metastasis of hormone-dependent malignancies, Int. J. Oncol. 1998, 12,  911-920. 
11
Vasiljeva, O.; Turk, B. Dual contrasting roles of cysteine cathepsins in cancer progression: 
Apoptosis versus tumor invasion, Biochimie, 2008, 90, 380-386. 
12
 Lopez-Otin, C.; Matrisian, L.M. Tumour microenvironment: Emerging roles of proteases in 
tumour suppression, Nat. Rev. Cancer, 2007, 7, 800-808. 
13
 Antalis, T. M.; Bugge, T. H. Proteases and cancer methods and protocols, Springer: New 
York, USA, 2009; 1-32. 
14
 Carroll, M. C.; The complement system in regulation of adaptive immunity, nature 
immunology, 2004, 5, 981-986. 
15
 Hoffman, M.; Monroe, D. M. Rethinking the coagulation cascade, Curr. Hematol. Rep. 2005, 
4, 391-396. 
16
 Szarvas, T.; Dorp, F. V.; Ergun, S.; Rubben, H. Matrix metalloproteinases and their clinical 
relevance in urinary bladder cancer, Nat. Rev. Urol. 2011, 8, 241-254. 
   36 
 
                                                                                                                                                             
17
  Serine proteases, Center for Biomolecular Imaging, 2008. 
18
 Tang, C. H.; Wei, Y. The urokinase receptor and integrins in cancer progression, Cell. Mol. 
Life Sci. 2008, 65, 1916 – 1932. 
19
 Huai, Q.; Mazar, A. P.; Kuo, A.; Parry, G. C.; Shaw, D. E.; Callahan, J.; Li, Y.; Yuan, C.; 
Bian, C.; Chen, L.; Furie, B.; Furie, B. C.; Cines, D. B.; Huang, M. Structure of Human 
Urokinase Plasminogen Activator in Complex with Its Receptor, Science,  2006, 311, 656-659. 
20
 Mazzieri, R.; Furlan, F.; Alessio, S. D.; Zonari, E.; Talotta, F.; Verde, P.; Blasi, F. A direct 
link between expression of urokinase plasminogen activator receptor, growth rate and 
oncogenic transformation in mouse embryonic fibroblasts, Oncogene, 2007, 26, 725-732.  
21
 Foda, H. D.; Zucker, S. Matrix metalloproteinases in cancer invasion, metastasis and 
angiogenesis, Drug Discovery Today, 2001, 6, 478-482. 
22
 Chabottaux, V.; Noel, A. Breast cancer progression: insights into multifaceted matrix 
metalloproteinases, Clin. Exp. Metastasis, 2007, 24, 647–656. 
23
 Egeblad, M.; Werb, Z., New functions for the matrix metalloproteinases in cancer progression, 
Nat. Rev. Cancer, 2002, 2, 161-174. 
24
 Bogenrieder, T.; Herlyn, M. Axis of evil: molecular mechanisms of cancer metastasis, 
Oncogene,  2003, 22, 6524-6536. 
25
 Lecaille, F.; Kaleta, J.; Bromme, D. Human and Parasitic Papain-Like Cysteine Proteases: 
Their Role in Physiology and Pathology and Recent Developments in Inhibitor Design, Chem. 
Rev. 2002, 102, 4459-4488. 
26
 Nomura, T.; Katunuma, N. Involvement of cathepsins in the invasion, metathesis, and 
proliferation of cancer cells, The Journal of Medical Investigation, 2005, 52, 1-9. 
27
 Bartsch, J. E.; Staren, E. D.; Appert, H. E. Matrix Metalloproteinase Expression in Breast 
Cancer, Journal of Surgical Research, 2003, 110, 383–392. 
28
 Tetu, B.; Brisson, J.; Lapointe, H.; Bernard, P. Prognostic significance of stromelysin 3, 
Gelatinase A, urokinase expression in breast cancer, Human Pathology, 1998, 29, 979-985. 
29 Kantelhardt, E. J.; Vetter, M.; Schmidt, M.; Veyret, C.; Augustin, D.; Hanf, V.; Meisner, C.; 
Paepke, D.; Schmitt, M.; Sweep, F.; Minckwitz, G.V.; Martin, P.; Jaenicke, F.; Thomssen, C.; 
Harveck, N. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast 
cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 
3 × FEC/3 × Docetaxel, BMC Cancer,  2011, 11, 1-10. 
30
 Riley, L. B.; Lange, M. K.; Browne, R. J.; Cochrane, P. J.; Choi, I.-J.; Davis, B.; Arcona, S.; 
Alhadeff, J. A. Analysis of cathepsin D in human breast cancer: usefulness of the processed 
   37 
 
                                                                                                                                                             
31kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive 
patients,  Breast Cancer Research and Treatment, 2000, 60, 173-179. 
31
 Foekens, J. A.; Kos, J.; Peters, H. A.; Krasovec, M.; Look,  M. P.; Cimerman,  N.; Meijer-Van 
Gelder, M. E.; Henzen-Logmans, S. C.; Van Putten, W. L. J.; Klijn, J. G. M. Prognostic 
significance of cathepsins B and L in primary human breast cancer,  Journal of Clinical 
Oncology,  1998, 16, 1013-1021. 
32 Muller, D.; Breathnach, R.; Engelmann, A.; Millon, R.; Bronner, G.; Flesch, H.; Dumont, P.; 
Eber, M.; Abecassis, J. Expression of collagenase-related metalloproteinase genes in human 
lung or head and neck tumours,  Int. J. Cancer, 1991,  48,  550–556. 
33
 Lakka, S. S.; Rajagopal, R.; Rajan, M. K.; Mohan, P. M.; Adachi, Y.; Dinh, D. H.; Olivero, W. 
C.; Gujrati, M.; Ali-Osman, F.; Roth, J. A.; Yung, W. K. A.; Kyritsis, A. P.; Rao, J. S. 
Adenovirus-mediated Antisense Urokinase-Type Plasminogen Activator Receptor Gene 
Transfer Reduces Tumor Cell Invasion and Metastasis in Non-Small Cell Lung Cancer Cell 
Lines, Clinical Cancer Research, 2001, 7, 1087-1093. 
34
 Werle, B.; Kotzsch, M.; Lah, T. T.; Kos, J.; Gabrijelcic-Geiger, D.; Spiess, E.; Schirren, J.; 
Ebert, W.; Fiehn, W.; Luther, T.; Magdolen, V.; Schmitt, M.; Harbeck, N. Cathepsin B, 
Plasminogenactivator-inhibitor (PAI-1) and Plasminogenactivator-receptor (uPAR) are 
Prognostic Factors for Patients with Non-small Cell Lung Cancer, Anticancer Research, 2004, 
24, 4147-4162.  
35
 Kos J.; Sekirnik, A.; Kopitar G.; Cimerman, N.; Kayser, K.; Stremmer, A.; Fiehn, W.; Werle, 
B. Cathepsin S in tumors, regional lymph nodes and sera of patients with lung cancer: Relation 
to prognosis,  British Journal of  Cancer , 2001, 85, 1193-1200. 
36
 Bühling, F.; Waldburg, N.; Krüger, S.; Röcken, C.; Wiesner, O.; Weber, E.; Welte, T. 
Expression of cathepsins B, H, K, L, and S during human fetal lung development, 
Developmental Dynamics, 2002, 225, 14-21.  
37
 Schmitt, M.; Sturmheit, A. S.; Welk, A.; Schnelldorfer, C.; Harbeck, N. Procedures for the 
quantitative protein determination of urokinase and  its inhibitor, PAI-1, in human breast 
cancer tissue extracts by ELISA, Methods in Molecular Medicine, Brooks, S. A.; Harris, A. L.; 
Humana Press Inc., Totowa, New Jersey, 2006, pp 245-265. 
38
  Johansson, N.; Ahonen, M.; Kähäri, V. -M. Matrix metalloproteinases in tumor invasion, 
Cellular and Molecular Life Sciences, 2000, 57, 5-15. 
39
 Chikkaveeraiah, B. V.; Bhirde, A. A.; Morgan, N. Y.; Eden, H. S.; Chen, X. Electrochemical 
immunosensors for detection of cancer protein biomarkers, ACS Nano, 2012, 6, 6546–6561. 
40
 Idikio, H. A. Immunohistochemistry in diagnostic surgical pathology: contributions of protein 
life-cycle, use of evidence based methods and data normalization on interpretation of 
immunohistochemical stains. Int. J. Clin. Exp. Pathol. 2010, 3, 169–176. 
   38 
 
                                                                                                                                                             
41
 Bishop, R. Applications of fluorescence in situ hybridization (FISH) in detecting genetic 
aberrations of medical significance, Bioscience Horizons, 2010, 3, 85–95. 
42
 Bossmann, S. H.; Troyer, D. L. Point-of-care routine rapid screening: the future of cancer 
diagnosis, Expert Rev. Mol. Diagn. 2013, 13, 107-109. 
43
  Khasigov, P. Z.; Podobed, O. V.; Gracheva, T. S.; Salbiev, K. D.; Grachev, S. V.; Berezov, T. 
T. Role of  matrix metalloproteinases and their inhibitors in tumor  invasion and  metastasis.  
Biochemistry, 2003, 68, 711-717. 
44
  Turk, B. E.; Huang, L. L.; Piro, E. T.; Cantley, L. C. Determination of protease cleavage site 
motifs using mixture-based oriented peptide libraries, Nature Biotechnology, 2001, 19, 661-
667. 
45
 Pham, W.; Weissleder, R.; Tung, C. -H. An azulene dimer as a near-infrared quencher, Angew. 
Chem. Int. Ed. 2002, 41, 3659-3662. 
46
 Pham, W.; Choi, Y.; Weissleder, R.; Tung, C. -H. Developing a peptide-based near-infrared 
molecular probe for protease sensing, Bioconjugate Chem. 2004, 15, 1403-1407. 
47
 Zhao, M.; Josephson, L.; Tang, Y.; Weissleder, R. Magnetic sensors for protease assays, 
Angew. Chem. Int. Ed. 2003, 42, 1375-1378. 
48
 Funovics, M.; Weissleder, R.; Tung, C.-H. Protease sensors for bioimaging, Anal. Bioanal. 
Chem. 2003, 377, 956-963. 
49
 Friedman, A. E.;  Chambron, J. -C.;  Sauvage, J. -P.; Turro N. J.; Barton, J. K. Molecular light 
switch for DNA: Ru(bpy)2(dppz)
2+
, J. Am. Chem. Soc. 1990, 112, 4960-4962. 
50 Simard, B.; Tomanek, B.; van Veggel F. C. J. M.; Abulrob, A. Optimal dye-quencher pairs for 
the design of an "activatable" nanoprobe for optical imaging, Photochemical & 
Photobiological Sciences, 2013, 12, 1824-1829. 
51Quillard, T.; Croce, K.; Jaffer, F. A.; Weissleder R.; Libby, P. Molecular imaging of 
macrophage protease activity in cardiovascular inflammation in vivo, Thromb. Haemos. 2011, 
105, 828-836. 
52 Welser, K.; Adsley, R.; Moore, B. M.; Chan, W. C.; Aylott, J. W. Protease sensing with 
nanoparticle based platforms, Analyst, 2011, 136, 29-41. 
53 Kim, G. B.; Kim, Y.-P. Analysis of protease activity using quantum dots and resonance energy 
transfer, Theranostics, 2012, 2, 127-138. 
54
 Pavan, S.; Berti, F. Short peptides as biosensor transducers, Anal. Bioanal. Chem. 2012, 402, 
3055-3070. 
   39 
 
                                                                                                                                                             
55
 Kobayashi, H.; Choyke, P. L. Target-Cancer-Cell-Specific Activatable Fluorescence Imaging 
Probes: Rational Design and in Vivo Applications, Acc. Chem. Res. 2011, 44, 83-90. 
56
 Huang, X.; El-Sayed I. H.; El-Sayed, M. A. Fluorescent quenching gold nanoparticles: 
potential biomedical applications, Metal enhanced fluorescence; Geddes, C. D. John Wiley & 
Sons, Inc., 2010, pp 573-599. 
57
 Lacroix, L.-M.; Huls, N. F.; Ho, D.; Sun, X.; Cheng, K.; Sun, S. Stable Single-Crystalline 
Body Centered Cubic Fe Nanoparticles, Nano Lett. 2011, 11, 1641-1645. 
58
 Wang, H.; Shrestha, T. B.; Basel, M. T.; Dani, R. K.; Seo, G. -M.; Balivada, S.; Pyle, M. M.; 
Prock, H.; Koper, O. B.; Thapa, P. S.; Moore, D.; Li, P.; Chikan, V.; Troyer D. L.; Bossmann, 
S. H. Magnetic-Fe/Fe3O4-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for 
the delivery to tumors within monocytes/macrophages, Beilstein J. Nanotechnol. 2012, 3, 444-
455. 
59
 Sobczynski, J.; Toennesen, H. H.;  Kristensen, S. Influence of aqueous media properties on 
aggregation and solubility of four structurally related meso-porphyrin photosensitizers 
evaluated by spectrophotometric measurements, Pharmazie. 2013, 68, 100-109. 
60 
Patsenker, L.; Tatarets, A.; Kolosova, O.; Obukhova, O.; Povrozin, Y.; Fedyunyayeva, I.; 
Yermolenko, I.; Terpetschnig, E. Fluorescent probes and labels for biomedical applications, 
Ann. N. Y. Acad. Sci. 2008, 1130, 179-187. 
61 Kalita, M.; Basel, M. T.; Janik, K.; Bossmann, S. H. Optical and Electronic Properties of 
Metals and Semiconductors in Nanoscale Materials in Chemistry, Nanoscale Materials in 
Chemistry,  Klabunde, K. J. Wiley & Sons: New York, USA, 2009; pp 539-578. 
62
 Tam, F.; Goodrich, G. P.; Johnson, B. R.; Halas, N. J. Plasmonic Enhancement of  Molecular 
Fluorescence, Nano Lett.  2007, 7, 496-501. 
63
 Song, E.; Cheng, D.; Song, Y.; Jiang, M.; Yu J.; Wang, Y. A graphene oxide-based FRET 
sensor for rapid and sensitive detection of matrix metalloproteinase 2 in human serum sample, 
Biosens. Bioelectron. 2013, 47, 445-450. 
64
 Swisher, L. Z.; Syed, L. U.; Prior, A. M.; Madiyar, F. R.; Carlson, K. R.; Nguyen, T. A.; Hua, 
D. H.; Li, J. Electrochemical Protease Biosensor Based on Enhanced AC Voltammetry Using 
Carbon Nanofiber Nanoelectrode Arrays, J. Phys. Chem. C, 2013, 117, 4268-4277. 
65
 Swedberg, J. E.; Harris, J. M. Natural and Engineered Plasmin Inhibitors: Applications and 
Design Strategies, ChemBioChem. 2012, 13, 336-348. 
66
 Perinchery, S. M.; Kuzhiumparambil, U.; Vemulpad, S.; Goldys, E. M. The potential of 
autofluorescence spectroscopy to detect human urinary tract infection, Talanta,  2010, 82, 912–
917. 
   40 
 
                                                                                                                                                             
67
 Herman, B. Fluorescence microscopy : State of the art, Fluorescence Microscopy and 
Fluorescent Probes, Slavik, J. Plenum Press, New York, 1996, pp 1-12. 
68
 Lakowicz, J. Principles of Fluorescence Spectroscopy, 3rd ed., Plenum, Springer: Singapore, 
2006. 
69
 Jeong, E.-Y.; Burri, A.; Lee, S. -Y.; Park, S. Synthesis and catalytic behavior of tetrakis(4-
carboxyphenyl) porphyrin-periodic mesoporous organosilica. J. Mater. Chem. 2010, 20, 
10869-10875. 
70
Scalise, I.; Durantini, E. N. Photodynamic effect of metallo 5-(4-carboxyphenyl)-10,15,20-
tris(4-methylphenyl) porphyrins in biomimetic AOT reverse micelles containing urease, 
Journal of Photochemistry and Photobiology A:Chemistry, 2004, 162, 105-113.  
71
 Johnson-White, B.; Zeinali, M.; Shaffer, K. M.; Patterson Jr. C. H.; Charles, P. T.; Markowitz, 
M. A. Detection of organics using porphyrin embedded nanoporous organosilicas. Biosensors 
and Bioelectronics, 2007, 22, 1154-1162.  
72
 Cherian, S.; Wamser, C. C. Adsorption and Photoactivity of Tetra(4-carboxyphenyl)porphyrin 
(TCPP) on Nanoparticulate TiO2, J. Phys. Chem. B, 2000, 104, 3624-3629. 
73
 Besschetnova, I. A.; Chudinov, A. V.; Kaluzhny, D. N.; Shchyolkina, A. K.; Borisova, O. F.; 
Tokalov, S. V.; Kuznetsova, V. E.; Lobanov, A. V.; Rumyantseva, V. D.; Barsky, V. E.; 
Mirzabekov, A. D. Fluorescence of meso-tetrakis[4-(carboxy)phenyl]porphine covalently 
bound to oligonucleotides d(CG)5 and d(TA)5, Biofizika, 2002, 47, 259-267.  
74
 Lambert, C. R.; Reddi, E.; Spikes, J. D.; Rodgers, M. A. J.; Jori, G. The effects of porphyrin 
structure and aggregation state on photosensitized processes in aqueous and micellar media, 
Photochem. Photobiol., 1986, 44, 595-601. 
75
 Buschmann, V.; Weston, K. D.; Sauer, M. Spectroscopic study and evaluation of red-
absorbing fluorescent dyes, Bioconjugate Chem. 2003, 14, 195-204. 
76
 Raikar, U. S.; Tangod, V. B.; Mastiholi, B. M.; Fulari, V. J. Fluorescence quenching using 
plasmonic gold nanoparticles. Optics Communications, 2011, 284, 4761-4765. 
77
 Mayilo, S.; Kloster, M. A.; Wunderlich, M.; Lutich, A.; Klar, T. A.; Nichtl, A.; Kurzinger, K.; 
Stefani, F. D.; Feldmann, J. Long-Range Fluorescence Quenching by Gold Nanoparticles in a 
Sandwich Immunoassay for Cardiac Troponin T. Nano Lett. 2009, 9, 4558-4563. 
78
 Ancukiewicz, D. Enhanced Light Emission Using Plasmonic Gold Nanoparticles, Optics & 
Opto-electronics, 2008, 100-101. 
79
 Yuan, L.; Lin, W.; Zheng, K.; Zhu, S. FRET-Based Small-Molecule Fluorescent Probes: 
Rational Design and Bioimaging Applications, Acc. Chem. Res. 2013, 46, 1462-1473.  
   41 
 
                                                                                                                                                             
80
 Lam, A. J.; St-Pierre, F.; Gong, Y.; Marshall, J. D.; Cranfill, P. J.; Baird, M. A.; McKeown, M. 
R.; Wiedenmann, J.; Davidson, M. W.; Schnitzer, M. J.; Tsien, R. Y.; Lin, M. Z. Improving 
FRET dynamic range with bright green and red fluorescent proteins, Nature Methods, 2012, 9, 
1-7. 
81
 Sapsford, K. E.; Berti, L.; Medintz, I. L. Materials for fluorescence resonance energy 
transferanalysis: Beyond traditional donor_acceptor combinations. Angew. Chem., Int. Ed. 
2006, 45, 4562–4588. 
82
 Ben-Avraham, D.; Schulman, L. S.; Bossmann, S. H.; Turro, C.; Turro, N. J. Luminescence 
Quenching of Ruthenium(II)-Tris(phenanthroline) by Cobalt(III)-Tris(phenanthroline) Bound 
to the Surface of Starburst Dendrimers, J. Phys. Chem. B, 1998, 102, 5088-5093. 
83
 Isacsson, J.; Westman, G. Solid-phase synthesis of asymmetric cyanine dyes. Tetrahedron 
Lett. 2001, 42, 3207-3210.  
84 
Fayed, T. A.; Extension of fluorescence response to the near -IR region, Reviews in 
Fluorescence, Geddes, C. D.; Lakowicz, J. R.;  Springer: New York, 2011, pp 75-111. 
85 
Nolting, D. D.; Gore, J. C.; Pham, W., Near-Infrared Dyes: Probe Development and 
Applications in Optical Molecular Imaging, Curr. Org. Synth. 2011, 8, 521-534. 
86
  Xu, D. -Q.; Yang, W. -L.; Luo, S. -P.; Wang, B. -T.; Wu, J.; Xu, Z. -Y.  Fischer Indole 
Synthesis in Brønsted Acidic Ionic Liquids: A Green, Mild, and Regiospecific Reaction 
System, Eur. J. Org. Chem. 2007, 1007–1012. 
87
 Pandey, R. K.; James, N.; Chen, Y.; Dobhal, M. P. Cyanine Dye-Based Compounds for Tumor 
Imaging With and Without Photodynamic Therapy, Top Heterocycl. Chem. 2008, 14, 41-74. 
88





 Suslick, K. S.; Fang, M.; Hyeon, T. Sonochemical Synthesis of Iron Colloids J. Am. Chem. 
Soc. 1996, 118, 11960–11961. 
91
 Li, J.; Wu, N. Biosensors based on nanomaterials and nanodevices, CRC Press: New York, 
USA, 2014. 
   42 
 
Chapter 2 - Synthesis of Magnetic-Nanoparticle (Fe/Fe3O4) - based 
Nanoplatforms for Highly Sensitive Fluorescence Detection of 
Cancer-Related Proteases 
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Sensitive Fluorescence Detection of Cancer-Related Proteases, Photochem. Photobiol. Sci. 2013, 
accepted. (this publication has dual first authorship of Dr. Wang and myself). 
 
 2.1 Design of the Nanoplatform 
 Fe/Fe3O4 nanoparticles were synthesized by thermal decomposition of Fe(CO)5 in 
the presence of oleylamine and hexadecylammonium chloride (HADxHCl) using 1-octadecene 
(ODE) as solvent.
1
 Figure 2.1 shows the transmission electron microscopy (TEM) images (1a, 
1b) and high-resolution transmission electron microscopy (HRTEM) image (1c) of the obtained 
nanoparticles. The nanoparticles have a well-defined core/shell structure, with the average Fe(0) 
core diameter of 13 ±0.5 nm and the Fe3O4 shell thickness of 2.0 ±0.5 nm, respectively. The 
HRTEM image reveals polycrystalline nature of the nanoparticles. Dopamine forms robust 






 It also increases the water-
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Figure 2.1: TEM (1a,1b) and HRTEM (1c) Images of Fe/Fe3O4 - Core/Shell Nanoparticles 
that are Forming the Inorganic Core of the Nanoplatforms for Protease Detection  
 
In Table 2.1, the consensus sequences that have been employed for detecting 12 
proteases, as well as the resulting lengths of the enzyme-cleavable tethers between nanoparticle 
and TCCP are summarized. Cyanine 5.5 was permanently linked to dopamine without using an 
enzyme-cleavable tether. Consequently, Cy 5.5 remains permanently bonded to the nanoparticle 
during the protease detection process. 
 
Table 2.1: Consensus Sequences in Single-Letter Code for 12 Proteases and Distance 






















































































 Molecular Modeling has been performed using an MM3 force field 
 
The Bossmann/Troyer group has explored the synthesis and application of Fe/Fe3O4-





 The synthesis Fe/Fe3O4-nanoparticles was achieved by following a synthetic 
procedure
5
 based on the work of S. Sun et al.
1
 Porphyrins have been used as effective 
photosensitizers in photodynamic therapy (PDT). Their photophysical properties are excellently 
characterized.
6
 Cyanine dyes have been widely used in DNA sequencing, genetic analysis, and 
in-vivo imaging due to their superior photochemical properties such as large molar extinction 
coefficients, moderate-to-high fluorescence quantum yields, and broad wavelength tunability.
7
 
Figure 2.2 shows the structure of the nanoplatform comprised of dopamine-coated Fe/Fe3O4 
nanoparticle, consensus sequence, TCPP, and Cy 5.5.  
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Figure 2.2: Nanoplatform for Protease Detection 
One Fe/Fe3O4-nanoparticle is linked in average to 35+/-3 TCPP-molecules via consensus 
sequence (one type of sequence per nanoplatform) and 50+/-4 cyanine 5.5 molecules via amide 
linkages. 
 2.1.1 Synthesis of Iron/Iron oxide - Fe/Fe3O4 Nanoparticles 
Iron nanoparticles were prepared with slight modification of a literature procedure 
described by Lacroix et al.
1
 A 250 mL, three-necked, round-bottom flask equipped with a 
magnetic stir bar, one cold water cooled jacket condenser on the middle neck, one septum and 
one temperature probe on each of the outer necks was charged with 60 mL 1-octadecene (ODE), 
0.9 mL oleylamine and 0.831 g hexadecylammonium chloride (HADxHCl). The reaction system 
was connected to a Schlenk line through the top of the jacket condenser. The reaction mixture 
was degassed at 120 
o
C for 30 min with vigorous stirring. After being refilled with argon, the 
reaction mixture was heated to 180
o
 C. Three portions of 0.7 mL Fe(CO)5 were injected into the 
reaction mixture via syringe, every 20 min. The reaction mixture was kept at 180 
o
C for another 
20 min after the last injection, and then cooled to room temperature naturally. The supernatant 
was decanted, and the iron nanoparticles accumulated on the magnetic stir bar were washed with 
hexane and ethanol. The product was dried in vacuum and stored at room temperature under 
argon for further use. Based on the iron content of the nanoparticles, which was determined 
spectrophotometrially after dissolving the nanoparticles in aqueous HCl (1.0 M) and subsequent 
complexation with ferrozine (sodium 4,4'-(3-(pyridin-2-yl)-1,2,4-triazine-5,6-diyl)dibenzene-
sulfonate)
8
, the yield of the reaction is 95%. 
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 2.1.2 Dopamine Coating of the Core/Shell Fe/Fe3O4 Nanoparticles 
0.50 g of previously synthesized Fe/Fe3O4 nanoparticles was dispersed in 100 mL 
chloroform via sonication. With vigorous mechanical stirring, a solution of 0.50 g dopamine-
hydrochloride in 50 mL chloroform was added drop-wise to the nanoparticle suspension. The 
reaction mixture was further stirred at room temperature for 24 h, and then the dopamine- coated 
nanoparticles were collected by centrifugation. After washing with chloroform 5 times, 
nanoparticles were dried under vacuum. 0.47 g dopamine coated Fe/Fe3O4 nanoparticles were 
collected.  
 2.2 Synthesis of peptides 
All the peptide sequences for all twelve proteases, which were utilized in this project 
have been synthesized in the Bossmann Laboratory.  
 2.2.1 Cancer-Specific Consensus Peptide Sequence Synthesis  
Cancer specific consensus peptide sequences were synthesized via standard Solid Phase 
Peptide Synthesis (SPPS).
9
 Briefly, preloaded trityl-resin was swelled in DCM for 20 min, after 
washing with DMF, Fmoc-protected amino acids were added sequentially with O-Benzotriazole-
N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU) as coupling agent in a mixture of 
diisopropylethylamine (DIEA) and DMF. Taking advantage of the solid phase synthesis, the 
porphyrin TCPP was conjugated to the N-terminal of peptide sequence under standard coupling 
conditions. Finally, the TCPP-labeled cancer specific consensus peptide sequence was cleaved 
from the solid phase using 95/2.5/2.5 TFA (Trifluoroacetic acid) /TIPS (triisopropylsilane) /H2O 
solution. The purity of the consensus sequences was examined by using HPLC (RP18 column 
using CF3COOH/H2O/CH3CN gradients, using a Waters 1525 binary pump HPLC station).
10
 For 
all 12 TCPP-labeled consensus sequences, the analytical purity exceeded 95 percent. They were 
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Coupling of the next activated 
amino acid 
n cycles 
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Figure 2.3: Principles of SPPS, Taken from Reference 11 
  
Figure 2.3 shows the principle of solid phase peptide synthesis.
11
 Here P, permanent side 
chain protecting group, T, temporary protecting group,      , solid support, A, activating group, 
and X, NH or O.  
 2.3 Synthesis of Cyanine dyes 
This cyanine synthesis is following environmentally friendly and cost-efficient methods. 
The starting point is the synthesis of indoles. For the n.0 series of the cyanine dyes, 2,3,3-
trimethyl-3H-indole and for the n.5 series 1,1,2-trimethyl-1H-benzo[e]indole should be used. To 
add the hydrophilic character to these cyanine dyes, we have selected hexanoic acid and 1,4-
butanesultone as alkyl substituents of the indole nitrogens. 
 2.3.1 Cyanine 5.5 Synthesis 
In order to synthesize the cyanine dye first the two ring components (indolium salts) 
should be synthesized. Then the two components can be linked through the appropriate linker. 
 2.3.1.1 Synthesis of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate (3) 
The synthetic procedure was a modification of reference 
12
. A 50 mL two necked round 
bottom flask fitted with a magnetic stirrer and a condenser was flame dried. 1,1,2-trimethyl-1H-
benzo[e]indole (1) (1.0 g, 4.78 mmol) was dissolved in dry o-dichlorobenzene (10 mL). 1,4-
butanesultone (2) (0.58 mL, 5.73 mmol) was added drop-wise under a continuous flow of argon. 
The reaction mixture was, then, allowed to heat up to 130
o
 C for 24 h. The reaction mixture was 
allowed to cool down to room temperature to obtain a blue colored precipitate. The precipitate 
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was triturated with ice-cold diethyl ether (40 mL) for 15 min. The precipitate was filtered 
through frit glass, washed with cold diethyl ether (3 x 5 mL), dried in vacuum yielding 0.70 g of 
compound 3. Percentage yield: 42%. 
1
H NMR (DMSO-d6, 400 MHz) δ (ppm): 8.36 (d, 1H), 
8.27 (d, 1H), 8.22 (s, 1H), 8.20(d, 1H), 7.76(dt, 2H), 4.60(t, 2H), 3.31(t, 2H), 2.0(qi, 2H), 








Figure 2.4: Synthesis of Indolium Salt 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-
yl)butane-1-sulfonate (3) 
 2.3.1.2 Synthesis of 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-benzo[e]indol-3-ium (5) 
 The synthetic procedure was a modification of reference 
12
. A two-necked 50 mL round 
bottom flask fitted with reflux condenser and stirring bar was charged with 1,1,2-trimethyl-1H-
benzo[e]indole, (1) (1.0 g, 4.78 mmol) which was flushed with argon three times. After 
dissolving in dry o-dichlorobenzene (15 mL), (0.93 g, 4.78 mmol) of 6-bromohexanoic acid (4) 
was added. The reaction mixture was stirred for 36 h at 120 
o
C by using an oil bath. This resulted 
in a dark blue solution. The reaction mixture was allowed to cool down to room temperature. 
This cooled solution was triturated with 1:1 diethyl ether and hexane mixture (total volume 90 
mL) for an hour. The blue precipitate was filtered off, washed with diethyl ether (3 x 20 mL) and 
dried in vacuum yielding 1.1 g of the compound 5. Percentage yield: 56%. 
1
H NMR (DMSO-d6, 
400 MHz) δ (ppm): 12 (br, s, 1H), 8.37 (d, J=8.4Hz, 1H), 8.29 (d, J=9Hz, 1H), 8.21 (d, J=7.8Hz, 
1H), 8.14 (d, J=8.8Hz, 1H), 7.79 (t, J=7.0Hz, 7.2Hz, 1H), 7.73 (t, J=7.2Hz, 1H), 4.57 (t, 




















Figure 2.5: Synthesis of Indolium Salt 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-
benzo[e]indol-3-ium (5) 
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The synthetic procedure was a modification of reference 
12
. A 50 mL two-necked oven 
dry round bottom flask fitted with a magnetic stir bar was flushed with argon. Indolium salt, (3) 
(0.1 g, 0.9 mmol) and malondialdehyde bis(phenylimine) monohydrochloride (6) (0.09 g, 0.35 
mmol) were charged into the 50 mL round bottom flask. Acetic anhydride (10 mL) was added to 
this mixture and slowly heated to 120 
o
C in an oil bath and the reaction was monitored through 
TLC. The reaction was allowed to remain at 120 
o
C for half an hour. The reaction was then 
cooled to room temperature. An indolium salt, (5) (0.175 g, 0.433 mmol) in dry pyridine (5 mL) 
was added to the above reaction dropwise. The reaction was allowed to stir at room temperature 
for 16 h. The mixture was, then, concentrated in rotavap and the residue was dissolved in CH2Cl2 
(3 mL) and loaded on silica column chromatography with CH2Cl2:MeOH solvent system (total 
volume = 2 L). A gradient of 100% to 25% of solvent CH2Cl2 was used to obtain 0.21 g of a 
deep blue colored dye. Percentage yield of cyanine 5.5: 92%. 
1
H NMR (DMSO-d6, 400 MHz) δ 
(ppm): 8.48 (t, J=12Hz, 2H), 8.24(d, J=8.2Hz, 2H), 8.06(m, 2H), 7.78(m, 1H), 7.67(m, 1H), 
7.51(m, 2H), 6.65(dd, J=8Hz, 1H), 6.44(d, J=12Hz, 1H), 6.33(d, J=12Hz, 1H), 4.23(m, 4H), 
3.0(m, 2H), 2.08(m, 2H), 1.96(m, 2H), 1.78(s, 16H), 1.57(m, 2H), 1.42(m, 2H) 
 
 2.4 Synthesis of (4-carboxyphenyl)porphyrin (TCPP) (11) 
 
The synthetic procedure was a variation of reference 
13
. 1.50 g 4-carboxybenzaldehyde 
(9) was dissolved in 80 mL acetic acid. The solution was warmed to 100 
o
C and a solution of 
0.67 g pyrrole (10) in 10 mL acetic acid was added dropwise over 20 min. Upon completion of 
addition, the solution was warmed to 120 
o
C slowly and was kept at 120 
o
C for 1 h. The mixture 
was cooled to 80 
o
C and 100 mL 95% ethanol was added and then lowered to room temperature, 
while stirring in 3 h. Then the mixture was kept in at -15 
o
C for 24 h. Purple solid was collected 
by vacuum filtration. The filter cake was washed with cold 50/50 ethanol/acetic acid (3×5 mL) 
and dried under high vacuum (oil pump) overnight. 0.51 g of pure product was obtained (25.5% 
yield). 
1
H NMR (DMSO-d6) δ: -2.94 (s, 2H); 8.35 (d, 8H); 8.39 (d, 8H); 8.86 (s, 8H); 13.31 (s, 
4H). 
13
C NMR (DMSO-d6) δ: 119.31; 127.90; 130.51; 134.44; 145.42; 167.46. MS-ESI+: m/z 
791.2. Molecular weight calculated as 790.2. 
 












Figure 2.7: Synthesis of (4-carboxyphenyl)porphyrin (TCPP) 
 
 2.5 Final Assembly of the Nanoplatforms for Protease Detection 
200 mg of dopamine coated Fe/Fe3O4 nanoparticles were dispersed in 5 mL of DMF. A 
solution of 3 mmol of Cy5.5, 3.3 mmol of EDC (1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide), 1 mmol of DMAP (4-Dimethylaminopyridine) in 1 mL of 
DMF was added to this dispersion. After sonicating for 1 h, the nanoparticles were precipitated 
by a magnet, and thoroughly washed with DMF (1 mL × 10). The recovered nanoparticles were 
redispersed in 5 mL of DMF, and to this dispersion, 2 mmol of TCPP linked peptide sequence, 
2.2 mmol of EDC, 1 mmol of DMAP in 2 mL of DMF were added. After sonicating for 1 h, the 
nanoparticles were precipitated by a magnet (0.55T), and thoroughly washed with DMF (1 mL × 
10). After drying in high vacuum, 170-185 mg of nanoplatform can be obtained. The 
composition of the nanoplatform was analyzed by means of UV-Vis spectroscopy (Agilent HP 
8543A). After combining all washing fractions and subsequent solvent removal in high vacuum, 
TCPP (log  (420 nm) = 5.65) and cyanine 5.5 (lg  (682 nm) = 5.17) were taken up in 1.0 ml 
methanol and quantitatively measured taking advantage of their high absorption coefficients. The 
nanoplatforms were dispersed in PBS, and TCPP and cyanine 5.5 were measured UV/Vis-
spectroscopically as well, using dopamine coated Fe/Fe3O4-nanoparticles in PBS as reference. 
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This resulting data, together with the size of the Fe/Fe3O4-nanoparticles, enables the calculation 
of the average ratio of TCPP and cyanine 5.5 per nanoparticle. 
 
 2.6 Control Experiments and Additional Photophysical Information 
 2.6.1 UV/Vis-absorption of the Nanoplatforms 
As shown in Figure 2.1, one Fe/Fe3O4-nanoparticle is linked in average to 35+/-3 TCPP-
molecules via consensus sequence (one type of sequence per nanoplatform) and 50+/-4 cyanine 
5.5 molecules via amide linkages. Assuming that all nanoplatforms feature an iron core of 13 nm 
in diameter, a Fe3O4 shell of 2 nm, and an outer dopamine layer of 1 nm, and that the weight of 








 and of dopamine is 1000 kg/m
3 
(estimated surface 
coverage 80 percent), the weight of one Fe/Fe3O4/dopamine nanoparticle is approx. 1.26 x 10
-20
 
kg = 1.26 x 10
-14 
mg. Furthermore, the weight of the attached dyes and consensus sequences does 
not exceed 1.5 percent of the total weight of the nanoplatform. Therefore, one mg contains 
approx. 7.9 x 10
13
 nanoplatforms. Since 50 cyanine 5.5 and 35 TCPP molecules are attached per 
nanoplatform, their concentrations are 3.96 x 10
-8
 moles and 2.77 x 10
-8
 moles per mg, 
respectively. 0.075 mg of each nanoplatform is added to 3.0 mL of PBS solution. The resulting 
TCPP concentration is 6.09 x 10
-7
 M. Based on this estimate, the observable TCPP absorption 
band at 421 nm should have an absorption of E = 0.23. 
   54 
 
 
Figure 2.8: UV/Vis-Absorption of the Nanoplatforms for Determining the Activities of 
MMP 1, MMP 7, and MMP 9 in PBS. 
The observed TCPP absorption peaks of the nanoplatforms (Figure 2.8) are significantly 
smaller (E = 0.1 to 0.07) and slightly broadened, indicating plasmonic coupling between the 
Fe/Fe3O4-nanoparticles and the tethered dyes. It is noteworthy that the cyanine 5.5 absorption 
band of the nanoplatforms is strongly broadened, and that its fluorescence is almost completely 
quenched. This behavior has been found for various dyes featuring small stokes shifts when 




 2.6.2. Plasmon Resonance Quenching 
Plasmon-resonance quenching
17 
between consensus-sequence bound TCPP and the 
dopamine-coated Fe/Fe3O4 nanoparticles was observed in the absence of co-tethered cyanine 5.5. 
The quenching of TCPP by Fe/Fe3O4 was static. The fluorescence intensity of TCPP in PBS at 
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298 K decreased from 72 to 47 percent, when tethered to Fe/Fe3O4, dependent on the length 
dynamics of the consensus sequence.
18
  
 2.6.2.1. TCPP Quenching in Dopamine-coated Fe/Fe3O4 Nanoparticles in the Absence of 
Cyanine 5.5 
A typical comparison of TCPP fluorescence spectra in the presence and absence of 
Fe/Fe3O4 is shown in the figure 2.9. Figure 2.9 shows the maximal fluorescence increase 
observed after incubating a nanoplatform consisting of dopamine-protected Fe/Fe3O4 
nanoparticles bound to TCPP, by means of the consensus sequence for MMP 2 (IPVS-LRSG) in 
PBS at 25 
o
C for 24 h. The observed increase in fluorescence intensity is 65%. 
 
 
Figure 2.9: Fluorescence Spectra of TCPP when bound to Fe/Fe3O4 Nanoparticles (32+/-4 





MMP 2 in PBS at 25 
o
C (B).  
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 2.6.2.2 Fluorescence Intensity Quenching of TCPP by Dopamine-coated Fe/Fe3O4-
Nanoparticles 
Figure 2.10 shows a Stern-Volmer plot of the integrated emission intensity of TCPP as a 
function of added dopamine-coated Fe/Fe3O4-nanoparticles. Two regions are clearly discernible: 
at very low nanoparticle concentrations, strong plasmonic resonance quenching is observed 






), whereas at increased concentrations light scattering by 
the nanoparticles leads to an enhancement in fluorescence from TCPP.
19
 This effect levels off at 
higher nanoparticle concentrations. 
 
Figure 2.10: Stern-Volmer Plot of the Fluorescence Intensity Quenching of TCPP 
(Integrated Intensities from 640 to 720 nm) by Dopamine-coated Fe/Fe3O4-Nanoparticles in 
PBS. 
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 2.6.3 Fluorescence Intensity Quenching of TCPP by Cyanine 5.5 







, which exceeds the limit of diffusion
20
 by one order of magnitude. 
These findings strongly support the assumption of Fluorescence Resonance Energy Transfer 
(FRET) between TCPP and Cy 5.5, although a linear Stern-Volmer plot is not necessarily in 
agreement with a classic dipole-dipole coupling mechanism and its inverse 6
th
 power dependence 




Figure 2.11: Stern-Volmer Plot of the Fluorescence Intensity Quenching of TCPP 
(Integrated Intensities from 640 to 720 nm) by Cyanine 5.5 in PBS. 
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 2.6.4. UV/Vis-Absorption and Fluorescence Spectra of TCPP in the Presence of 
Dopamine-Coated Fe/Fe3O4 Nanoparticles 
It is noteworthy that the absorption and emission spectra of TCPP do not indicate 
clustering, when dissolved in PBS at pH=7.4, mixed with dopamine-coated Fe/Fe3O4-
nanoparticles, or tethered to the Fe/Fe3O4-nanoparticles. Bathochromic shifts in TCPP absorption 
(Figure 2.12) and emission (Figure 2.13) spectra, which would indicate aggregation
21
, are not 
discernible.  
 
Figure 2.12: UV/Vis-Absorption Spectra of TCPP in PBS in the Presence of Increasing 
Concentrations of Dopamine-Coated Fe/Fe3O4 Nanoparticles.  
 
These nanoparticles are virtually identical with these employed in the nanoplatforms for 
protease detection. Nanoparticle concentrations: 0.00167 mg mL
-1
, 0.005 mg mL
-1
, 0.0083 mg 




, 0.0117 mg mL
-1
, 0.015 mg mL
-1
, 0.02 mg mL
-1
, 0.0267 mg mL
-1





, 0.10 mg mL
-1
, 0.167 mg mL
-1 
 
Figure 2.13: Fluorescence Spectra of TCPP in PBS in the presence of Increasing 
Concentrations of Dopamine-Coated Fe/Fe3O4 nanoparticles 
 
These nanoparticles are virtually identical with these employed in the nanoplatforms for 
protease detection. Nanoparticle concentrations: 0.00167 mg mL
-1
, 0.005 mg mL
-1
, 0.0083 mg 
mL
-1
, 0.0117 mg mL
-1
, 0.015 mg mL
-1
, 0.02 mg mL
-1
, 0.0267 mg mL
-1





, 0.10 mg mL
-1
, 0.167 mg mL
-1
. 
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 2.6.5 Nonaggregation of TCPP 
This is in agreement with the literature: the aggregation constant of TCPP in aqueous 






 The TCPP 
concentrations employed in this study are three orders of magnitude lower.  
 
Figure 2.14: UV/Vis-Absorption Spectra of TCPP in PBS (5.05 x 10
-8
 M, 3.25 x 10
-7
 M, 5.05 
x 10
-7
 M).  
The maxima of the Soret bands are at 416 +/- 1 nm, indicating that TCPP does not 
aggregate at pH = 7.4 at the chosen concentrations. 
 
At the same time, TCPP will remain linked to half of the consensus sequence, making the 
porphyrin distinctly more water-soluble. The octanol/water partitioning coefficients (log P)
23
 of 
TCPP and TCPP-peptide adducts are summarized in Table 2.2.  
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Table 2.2: Octanol/Water Partitioning Coefficients, Calculated by Using Chemdraw Ultra 
(version 12.0.3.1216) 
Protease Consensus Sequence 
Log P when tethered to 
TCPP at pH 7.4 
H2TCPP (pH=2)  9.6 
H2TCPP (pH=7)  7.6 
MMP 1 VPMS- 4.1 
MMP 2 IPVS- 4.6 
MMP 3 RPFS- 3.7 
MMP 7 VPLS- 4.5 
MMP 9 VPLS- 4.5 
MMP 11 GGAAN- 3.2 
MMP 13 GPQGLA- 2.9 
uPA SGR- 4.7 
CTS B SLLKSR- 1.7 
CTS D SLLIFR- 3.4 
CTS K GPR- 4.5 
CTS L SGVVIA- 3.5 
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Chapter 3 - Calibration of Magnetic-Nanoparticle (Fe/Fe3O4) - 
based Nanoplatforms for Highly Sensitive Fluorescence Detection of 
Cancer-Related Proteases 
 3.1 Validation of the Nanoplatform Designed for Measuring MMP 13 
The nanoplatform for detecting the activity of MMP 13 was incubated with three 
different concentrations of the enzyme (commercially available from Enzo Lifesciences) under 
sstandard cconditions at 298 K as a function of time. In short, 3.0 mL of PBS/dextran (10 mg 
dextran in 1.0 ml of PBS) were mixed with 75 µL of the nanoplatform dispersion (1.0 mg in 1.0 
ml of PBS) and 30 µl of the protease at each concentration level in PBS. In Figure 3.1, the results 




 of MMP 13 are shown. The nanoplatform shows the typical “Light Switch 
Effect”: TCPP (partially) escapes the quenching influence of Fe/Fe3O4 and the co-tethered 
cyanine 5.5. Consequently, its fluorescence quantum efficiency increases. Fluorescence increase 





 of MMP 13 is shown in Figure 3.1. 
 
Figure 3.1: Light Switch Effect of the Fe/Fe3O4 Nanoplatform Capable of Detecting MMP 
13 
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In Figure 3.2, the fluorescence increase of the nanoplatform capable of detecting MMP 















 of MMP 13 is shown. As anticipated for a 
matrix metalloproteinases, Michaelis-Menton kinetics is, principally, observed: the increase in 
reaction  rate is limited with increasing substrate concentration.
1 
                                  
 
Figure 3.2: Fluorescence Increase when Incubating the Fe/Fe3O4-Nanoplaform Capable of 
Detecting MMP 13 as a Function of Reaction Time  
 
The experiment which has done to obtain the results shown in Figure 3.2 is carried out 













. The TCPP fluorescence is integrated from λ= 620 nm to 680 nm. At the highest protease 





 is the upper bound of the concentration range of clinical interest, we have not 
adjusted the concentration of the nanoplatform to measure higher protease activities. 
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3.2 The Nanoplatform Designed for MMP 13 is Not Activated by MMP 9 or 
When Using a Scrambled Peptide Sequence Instead of the Consensus 
Sequence 
The next step of the nanoplatform validation process consisted in testing a scrambled 
version of the consensus sequence for MMP 13: GRPGAGQVQLGI as a component of a 




 of MMP 13 and incubating at 298 K for 60 min, 
the fluorescence increased to I/I
0
 = 1.06, indicating that the reaction of MMP 13 with the 
scrambled sequence is 51 times slower. (I: TCPP fluorescence intensity after 60 min. of 
incubation, I
0
: TCPP fluorescence intensity before incubation). This is shown in Figure 3.3. 
 It should be noted that a fraction of the observed increase in fluorescence could also 
occur from desorption of peptide-sequence attached TCPP that has been physisorbed at the 
dopamine coated Fe/Fe3O4 surface during the synthesis procedure because of competitive 
absorption of the enzyme. The nanoplatform did not show a measurable increase in fluorescence 
when dispersed in PBS, due to thorough washing procedures during synthesis.  
 
Figure 3.3: Fluorescence Spectra of the Nanoplatform for MMP 13 in the Absence of the 




 of MMP 9 
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The third validation procedure entailed incubation of the nanoplatform designed for 




 of MMP 9 and incubating at 
298 K for 60 min, the fluorescence increased to I/I
0
 = 1.027, which is 114 times slower. This is 
also shown in Figure 3.3. This experiment added further confidence in the selection of previously 
established consensus sequences from the literature, as described above. According to Figure 3.3,  
the “wrong” protease failed to activate the nanoplatform. Also it shows the fluorescence 
occurring from a nanoplatform using a scrambled version of the consensus sequence 




 of MMP 
13. Both nanoplatforms were incubated under standard conditions. 
3.3 Calibration of 12 Nanoplatforms Designed for Measuring the Activities of 
12 Cancer-Related Proteases 
After establishing the initial validation experiments using the nanoplatform designed for 
MMP 13, we have performed successful calibration procedures for all 12 nanoplatforms in the 








. Each nanoplatform comprised a dopamine-
coated Fe/Fe3O4-nanoparticle, and, in average, 50+/-4 permanently tethered cyanine 5.5 
molecules and 35+/-3 consensus-sequence-bound TCCP fluorophores. To avoid possible 
misunderstandings, we would like to emphasize again that each nanoplatform is capable of 
measuring one protease, multitasking was not attempted in the work described here. In following 
the outcome of the preliminary experiments described above, all nanoplatforms have been 
incubated in PBS in the presence of the anti-coagulation agent dextran at 298 K for exactly 60 
min. The fluorescence was measured at t = 0 min. and t = 60 min. The fluorescence signal was 
integrated from 620 nm to 680 nm. 
 A control sample, to which no protease was added, was incubated for 60 min. and then 
measured also to detect systematic errors occurring from nanoplatforms releasing TCPP for 
reasons other than enzymatic activity. For all investigated nanoplatforms (see Table 1.4), there 
was virtually no detectable increase in fluorescence after 60 min. of incubation in the absence of 
added protease (I/I
0
 < 1.05). The I/I
0
 response as a function of protease concentration was 
recorded by dividing the integrated fluorescence signal after 60 min. in the presence of the 
protease at respective concentration, I, by the reference signal obtained under (otherwise) 
identical conditions in the absence of the protease, I
0
ref.  For the majority of proteases, three 
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repetitions of the calibration procedure established a relative error under 2 percent, which is 
sufficient for clinical applications.
2 
The calibration of uPA needed seven repetitive calibration 
procedures to achieve the required precision, MMP9 and cathepsin L required five. Based on our 
calibration results, we have found three principal groups: 
 3.3.1 The Highly Reactive Proteases 
The group of proteases that causes the fastest increase of fluorescence intensity upon 
enzyme activation of their respective nanoplatforms is comprised of  MMP 7, MMP 11, MMP 
13, and cathepsin L, MMP 13 being the most reactive (Figure 3.4). For these three MMPs, the 
plots of I/I
0
ref vs. log c are fairly linear, indicating that the Michaelis-Menton plateau was 
approached, but not reached, within the region of clinical interest. Both I and I
0
ref were obtained 
after 60 min. of incubation at 298 K under standard conditions. 
 
Figure 3.4: Calibration Results for MMP 7, MMP 11, MMP 13, and Cathepsin L after 60 
min. of Incubation at 298 K Under Standard Conditions 
 




.  In order to avoid 
systematic errors, these measurements have to be precisely timed. 
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 3.3.2 The Moderately Reactive Proteases 
The nanoplatforms for measuring MMP 1, MMP 2, MMP 3, cathepsin B and cathepsin D 
show less pronounced fluorescence increases after 60 min. of incubation, compared to the 
nanoplatforms for the first group of proteases (Figure 3.5). The Michaelis-Menton plateau was 
not reached for any of these proteases. 
 
 
Figure 3.5: Calibration Results for MMP 1, MMP 2, MMP 3, Cathepsin B and Cathepsin D 
after 60 min of Incubation at 298 K under Standard Conditions
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With respect to future clinical diagnostics, it is of importance that the somewhat lower 
increases in fluorescence intensities upon incubation that were observed for the nanoplatforms 
designed for the second group of proteases do not impede any future applications of the 
nanoplatforms, because the experimental error from independent calibration procedures is less 
than 2 percent. This considerably low error permits the identification of the correct order of 
magnitude for every protease that was investigated. 
 3.3.3 The Group of Proteases Defying the “Light Switch” Paradigm 
From a mechanistical standpoint, the group comprising the nanoplatforms designed for 
measuring uPA, MMP 9 and cathepsin K is most interesting, because they show a decrease and 
not an increase of I/I
0
ref after incubation with their respective proteases. Again, we were able to 
reach an experimental error from three or more independent calibration procedures of less than 2 
percent, demonstrating that also the third group of nanoplatforms is potentially clinically viable. 
But why does their fluorescence decrease, in spite of fluorescence resonance energy 
transfer quenching (FRET)
3
 and plasmon-resonance quenching
4 
that are equally viable 
deactivation pathways in all of the nanoplatforms?  According to Table 2.1 (see page 56), we 
have employed consensus sequences of different lengths. uPA and cathepsin K are among the 
shortest sequences used, and one may expect that the shorter distance between TCPP and the 
nanoparticle may result in an increase of TCPP fluorescence when bound. Although the plasmon 
absorption of the Fe-core in Fe/Fe3O4-nanoparticles is distinctly weaker than of a gold 
nanoparticle, there is a discernible plasmon-dye interaction.
5
  
Furthermore, Fe/Fe3O4-nanoparticles scatter the incident light efficiently, which also may 
enhance the light absorption by TCPP when tethered.
6
 In both cases, cutting TCPP loose will 
result in a decrease of fluorescence intensity. For MMP 9, this case is harder to make, because 
the lengths of the consensus sequences for MMP 1, MMP 3, MMP 7, and MMP 9 are of 
comparable length. However, the reactivity that is observed with MMP 9 can be better 
understood when looking at the observed activities of all nanoplatforms for protease 
measurements.
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Figure 3.6: Calibration Results for uPA, MMP 11, MMP 9, and Cathepsin K after 60 min. 
of Incubation at 298 K under Standard Conditions 
 
 3.4 Dependence of Fluorescence Activation Upon the Length of the Consensus 
Sequence 
The plots of I/I
0
ref vs. log c are sufficiently linear (R
2
 > 0.95 for all proteases except 









analyzed) to permit their analysis according to: I/I
0
ref = kmax + k log [c (protease)]. MMP 2 was 
identified as an outlier among the group of MMPs. In this study, uPA does not belong to a group 
of proteases. The resulting k-values for each protease were then plotted vs. the length of the 
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Although MM3 is a simple force field and cannot account for the dynamics of the 
oligopeptides, this simple analysis offers an interesting mechanistic insight into the reactivity of 
the nanoplatforms designed for analysing MMPs and cathepsins with their respective enzymes.  
Most interestingly, the “Light Switch” Effect intensifies with increasing distance between 





increase with decreasing distance. According to the literature, plasmon-
resonance quenching, also known as dipole-surface energy transfer (SET), shows inverse 4
th
 
power dependence in energy transfer efficiency.
8 





, although this assumption is not necessarily in agreement with the 
linear Stern-Volmer plot reported in Figure 2.11 (see page 70). 
 
 
Figure 3.7: Plot of the kinetic Constant k 
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In figure 3.7, The K has been obtained from the concentration dependence of the 
observed fluorescence increase/decrease for each enzyme, vs. the length of the consensus 
sequence that was used to tether TCPP and the Fe/Fe3O4-nanoplatform. 
It is apparent that the groups of nanoplatforms for measuring MMPs and cathepsins have 
different linear responses to the increase in tether length. The fluorescence increase of the group 
of nanoplatforms for MMP detection (R
2
 = 0.968) proceeds 3.2 times faster with increasing 
tether lengths than for the group of nanoplatforms for cathepsin detection (R
2
 = 0.979). MMP9 is 
among the sub-group of MMP’s with the least activity. 
There  is a possible explanation for the observed behavior (or combinations thereof): 
longer consensus sequences allow the proteases better access and, therefore, faster hydrolytic 
cleavage is observed. TCPP, which is tethered to the “tip” of the oligopeptides causes significant 
sterical hindrance. In agreement with our mathematical analysis of FRET occurring at the surface 
of the nanoplatforms, the longer consensus sequences may “bend back”, leading to a better 
contact between TCPP and the cyanine-5.5 tethered Fe/Fe3O4-nanoparticle. 
 3.5 Experimental Procedures 
 3.5.1 UV/Vis-Absorbance and Fluorescence Measurement 
Both experiments were carried out in 4.0 mL quartz-cuvettes (Helma) using a 
spectrofluoro-meter (Fluoromax2) with dual monochromators and a diode array UV-vis 
absorption spectrometer (HP 8453). PBS buffer (phosphate buffered saline (8 g NaCl, 0.2 g KCl, 
1.44 g Na2PO4, 0.24 g KH2PO4, dissolved in 1 l of bidest H2O), pH=7.2) was used as solvent. 
 3.5.2 Standard Procedure of Preparing Protease Assays: 
3.0 mg of nanoplatform are dissolved in 3 mL of PBS. The dispersion is sonicated for 10 
min. The resulting dispersion is chemically stable for 14 d at 277 K. 900 mg of dextran are 
dissolved in 90 mL of PBS. 
Stock solutions of all 12 enzymes were prepared by consecutive dilution of commercially 
available proteases (Enzo Lifesciences). 
3 ml of PBS/dextran (10 mg dextran in 1.0 mL of PBS) are mixed with 75 µL of the 
nanoplatform dispersion (3.0 mg in 3.0 mL of PBS) and 30 µL of the protease at each 
concentration level in PBS. 
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Chapter 4 - Detection of Breast And Lung Cancer Using Magnetic-
Nanoparticle (Fe/Fe3O4)-based Nanoplatforms for Highly Sensitive 
Fluorescence Detection of Cancer-Related Proteases  
 4.1 Background 
The validated protease assays (as described in chapter 2) were used for the analysis of 
biospecimens, instead of commercially available enzymes. The analysis work of this dissertation 
started with canine urine samples. A series of urine samples was analyzed using the protease 
assay for MMP 9 and urokinase. Urine samples from lymphoma dogs and healthy dogs were 
analyzed, which were collected by Prof. Dr. Mary Lynn Higginbotham in the Department of 
Anatomy & Physiology at Kansas State. Based on these results, we could basically identify two 
protease concentration levels for the two sets of samples. Which means, the low protease 
concentration range for the urine samples of healthy dogs and high protease concentration range 
for the urine samples of lymphoma dogs could clearly be distinguished. Since information about 
the stage of the cancer was unavailable, and the data were obtained only for two types of 
proteases, the canine urine analysis was not significant enough to approach valuable conclusions.  
Our next step was to analyze human urine samples. We received 36 human urine and 36 
human blood samples from Dr. Tracy Chapman, Southeastern Nebraska Cancer Center (SNCC). 
Among them 12 are from non small cell Lung cancer patients, 18 are from breast cancer patients 
(all forms of breast cancer) and 6 are from healthy human subjects. We started with MMP 9 
assay for both human urine samples and human blood samples. It is noteworthy that the viscosity 
of the blood samples was elevated, compared with commercially available proteases in PBS, thus 
causing some concern.  
Blood serum could be obtained from the blood samples by centrifugation. First the frozen 
blood vial was thawed in a water bath at 40 
0
C for 1 h. Then it was centrifuged for 10 min at 
10,000 RPM. Subsequent to this procedure, the red and white blood cells were collected at the 
bottom and a clear yellowish solution remains on the top. The supernatant is the blood serum, 
which was used for measuring protease activities with the protease assays.
1
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 4.1.1 Procedure for the Protease Assay 
All the solutions were prepared as stock solutions. Since the amounts of chemical 
required for protease measurements can be simplified to the concentrations needed for one 
sample, the procedure will be given per sample. Depending on the number of samples to analyze 
at a time, all the calculations can be done accordingly by simple multiplication. 
In a 15 mL centrifuge tube 75 L of the assay probe was added with the concentration of 
1 mg/mL. Then 30 µLof the biospecimen was added. It could be either human urine or human 
blood serum. Then the whole volume was increased to 3.0 mL using 1X PBS containing 10 
mg/ml of dextran. Then the tubes were sonicated for 5 min. and incubated it for one hour at 
25
o
C. At the end of the one hour of incubation, fluorescence measurements were performed. All 
samples were repeated in triplicates. Also assay control and biospecimen controls were 
performed. An assay control consisted of the assay probe only, without having any urine or 
blood serum added. Biospecimen control consisted only of the biospecimen in PBS/dextran, 
without having any assay probe. The experimental parameters of these experiments were same as 
described in chapter 2.  
 4.1.2 MMP 9 Assay for Human Blood Serum 
According to Figure 4.1, expression of MMP 9 was elevated in breast cancers. Stages III 
and IV were prominent among them. The integrated values has been calculated by taking the 
integral of the fluorescence spectra within the range 620 nm to 680 nm. 
 
Figure 4.1: Comparison of Different Cancers and Staging using Blood Samples 
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 4.1.3 MMP 9 Assay for Human Urine 
According to Figure 4.2, the data from urine samples was not as significant as the data 
from blood samples (Figure 4.1) that were previously investigated. 
 
Figure 4.2: Comparison of Different Cancers using Urine Samples 
 
Figure 4.3: MMP 9 - Blood & Urine Comparison 
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As the data for the urine analysis was not significant, we thought of comparing the blood 
serum assay data and urine assay data with same set of samples. According to Figure 4.3, there 
was no correlation of the data from blood serum analysis and urine analysis. So we decided to 
proceed only with blood serum data analysis but to abandon the human urine analysis.   
 4.2 Introduction 
 4.2.1 Blood 
Blood consists of at least 4000 different components, but the main four components are 
red blood cells, white blood cells, platelets, and plasma. Blood works as oxygen and nutrient 
transporter to cells. Also it transports metabolic waste products, such as carbon dioxide and 
ammonia.
2
 Higher volume of the blood such as 55% is covered with plasma. Plasma consists of 
blood clotting factors, sugars, fats, vitamins, minerals, hormones, enzymes, antibodies and 
proteins. 
 4.2.2 Blood Serum 
When the clotting elements are removed from the blood plasma, blood serum is obtained. 
Blood serum can be attained by allowing the blood to clot and squeezing out the yellow liquid. 
Most of the blood tests are carried out using blood serum, because it is long-term stable. 




 4.2.3 Urine 
Urine is the liquid that consists of numerous waste products from our metabolism. Urea is 
the main nitrogenous waste product in urine. The urinary bladder is the storage organ for the 
urine. It is excreted from the urethra.
4
 Approx. 95% of urine consists of water. Other components 
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 4.3 Results  
Protease assays were carried out for several proteases using the blood serum samples 
from 12 Lung cancer patients, 18 breast cancer patients and 6 healthy humans. Codes of the 
samples are as follows. 
Table 4.1: Codes of the Blood Samples 
Breast Cancer Lung Cancer Healthy Humans 
NS 2011 - 001B NS 2011 - 004L NS 2011 - 002C 
NS 2011 - 003B NS 2011 - 007L NS 2011 - 005C 
NS 2011 - 006B NS 2011 - 009L NS 2011 - 008C 
NS 2011 - 010B NS 2011 - 012L NS 2011 - 017C 
NS 2011 - 011B NS 2011 - 016L NS 2011 - 019C 
NS 2011 - 013B NS 2011 - 018L NS 2011 - 024C 
NS 2011 - 014B NS 2011 - 025L  
NS 2011 - 020B NS 2011 - 026L  
NS 2011 - 022B NS 2011 - 030L  
NS 2011 - 023B NS 2011 - 032L  
NS 2011 - 027B NS 2011 - 038L  
NS 2011 - 028B NS 2011 - 041L  
NS 2011 - 029B   
NS 2011 - 033B   
NS 2011 - 034B   
NS 2011 - 036B   
NS 2011 - 037B   
NS 2011 - 040B   
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 4.3.1 Calculations Associated with Data 
 First the average of the two consecutive scans for each sample was calculated. Then the 
average of the triplicates per each sample was calculated. From that final average data set, the 
integrated fluorescence value (S) was taken from 620 nm to 680 nm wavelength range of the 
sample. In a similar manner from the assay control (A) and blood serum control (B) samples, the 
integrated fluorescence value of the average data set was taken from 620 nm to 680 nm 
wavelength range. Then the difference between the two values S and B was calculated in order to 
avoid the autofluorescence occurring from the blood serum sample. Next step was to get the ratio 
of (S-B) and (A). This step was done to obtain information of the fluorescence increasement 
compared to the assay control. With the assay control there is some amount of TCPP, which is 
not quenched enough to avoid fluorescence. So this fluorescence should not mislead us to think 




in all the charts. 
 4.3.2 Study of MMP 1 Protease Assay Data  
 
Figure 4.4: Structure of MMP 1
5
 
MMP 1 is the interstitial collagenase, which is expressed abundantly within the human 
body. It degrades fibrillar collagens and the extracellular matrix.  It is one of the highly 
upregulated mRNAs in ADHC (Atypical Ductal Hyperplasia Cancer). The overexpression of 
MMP 1 mainly associates with incidence or invasiveness of the cancer.
6
 From the cell surfaces 
or matrix, MMP 1 releases pro-TGFα, other EGF like ligands and TGFβ. They are signaling 
molecule precursors which can result in  autocrine or paracrine signaling  with the tissue 
environment.
7,8 
The structure of the MMP 1 is shown in Figure 4.4 and the molecular weight of 
MMP 1 is 52000 Da.  




Figure 4.5: Integrated Fluorescence of the Blood Samples for MMP 1 Assay 
 
In figure 4.5 the integrated fluorescence data for all the blood serum samples and in 




values for all the blood serum samples are shown. The majority of the 




value. Based on the 
validation shown in Chapter 3, MMP 1 is a moderately reactive protease.  
 
Figure 4.6: Comparison of Blood Samples for MMP 1 
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 4.3.3 Study of MMP 2 Protease Assay Data  
MMP 2 is mostly involved in tumor invasion and metastasis processes. MMP 2 can be 
mainly found in fibroblasts, osteoblasts, endothelial cells and macrophages. MMP 2 secretion 
can be performed by the tumor cells. It can degrade the basement membrane. That means MMP 
2 can degrade the key components of the basement membrane such as gelatin and type IV 
collagen. There is a link between the tumor spread and the degradation of the basement 
membrane.
9,10
 The structure of the MMP 2 is shown in Figure 4.7 and the molecular weight of 
MMP 2 is 71000 Da. 
 
 





Figure 4.8: Integrated Fluorescence of the Blood Samples for MMP 2 Assay 
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In Figure 4.8 the integrated fluorescence data for all the blood serum samples and in 




values for all the blood serum samples are shown. The majority of the 




values above 1.0. Based on the 
validation shown in Chapter 3, MMP 2 is a moderately reactive protease. 
 
Figure 4.9: Comparison of Blood Samples for MMP 2 
 4.3.4 Study of MMP 7 Protease Assay Data  
 
Figure 4.10: Structure of MMP 7
5
 
MMP 7 is the smallest member of the MMP family. The structure of MMP 7 is shown in 
Figure 4.10 and the molecular weight of MMP 7 is 28000 Da. MMP 7 is also involved in tumor 
invasion and metastasis. MMP 7 has a wide substrate range against ECM and non ECM 
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components. Cellular transformation, cell survival, tumor growth, angiogenesis, and evasion of 




Figure 4.11: Integrated Fluorescence of the Blood Samples for MMP 7 Assay
 
 





values for all the blood serum samples are shown. The majority of the breast and 




values above 1.5. Based on the validation shown 
in Chapter 3, MMP 7 is a highly reactive protease. 
 
 
Figure 4.12: Comparison of Blood Samples for MMP 7 
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 4.3.5 Study of MMP 9 Protease Assay Data  
 




In Figure 4.13 the structure of MMP 9 is shown. The molecular weight of MMP 9 is 
92000 Da. Digestion of the subendothelial basement membrane, which is catalyzed by MMP 9, 
is regarded to be the first step in the intravasation and extravasation of cancer cells. Degradation 
of the main component of the basement membrane, which is the type IV collagen, is performed 
by the two structural proteins, MMP 2 and MMP 9. MMP 9 is a type IV collagenase (gelatinase 
B). It is produced mainly in neutrophils and macrophages. Previous studies show that with breast 
cancer, MMP 9 is expressed in macrophages, located adjacent to the invading tumor front.
13
 
MMP 9 is also expressed in NSCLC tumor cells and the surrounding stromal cells. But MMP 9 





Figure 4.14: Integrated Fluorescence of the Blood Samples for MMP 9 Assay 
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In Figure 4.14 the integrated fluorescence data for all the blood serum samples and in 




values for all the blood serum samples are shown. Almost all of the blood 




values above 1.0. Based on the validation shown in Chapter 3, MMP 
9 is a protease, which has defied the light switch paradigm. However, in blood serum, there are 
thousands of proteins present, which complicate the picture, because they are capable of 
adsorbing either at the nanoplatform or capable of adsorbing TCPP after it has been cleaved off 
by its respective protease. Light scattering studies of the nanoplatforms in PBS, in the presence 
of model proteases and blood serum, which will be presented in chapter 8, clearly indicate that 
the size of the formed assemblies depends on the proteins (proteases and/or proteins in blood 
serum) added to the mixture. Furthermore, all of these measurements are concentration 
dependent. Therefore, the calibration data obtained with commercially available enzymes in PBS 
cannot simply be applied when the protease contents of biospecimens is determined. This 
observation is especially important when measuring MMP 9 and urokinase plasminogen 
activator (uPA), which both have defied the light switch paradigm, meaning that their (TCPP) 





Figure 4.15: Comparison of Blood Samples for MMP 9 
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4.3.6 Study of MMP 13 Protease Assay Data  
 




In Figure 4.16 the structure of MMP 13 is shown. It's molecular weight is 52000 Da. 
MMP 13 is the main collagenase and it is known as collagenase 3. The main role of MMP 13 is 
the degradation of the ECM as most of the MMPs do. It is overexpressed in several types of 
malignant tissues. Depending on the type of the tumor, the expression distribution of MMP 13 by 
tumor cells and stromal cells are different. MMP 13 is actively involved in the activation of other 
MMPs. According to the literature the production of MMP 13 is performed either by tumor 




Figure 4.17: Integrated Fluorescence of the Blood Samples for MMP 13 Assay 
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In Figure 4.17 the integrated fluorescence data for all of the blood serum samples and in 




values for all the blood serum samples are shown. No significant 
differences between the blood samples from healthy humans and blood samples from cancer 
patients are discernible. Based on the validation shown in Chapter 3 MMP 13 is a highly reactive 
protease. 
 
Figure 4.18: Comparison of Blood Samples for MMP 13 
 
 4.3.7 Study of uPA Protease Assay Data  
 
Figure 4.19: Structure of Urokinase
5
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The Urokinase plasminogen activator (uPA) structure is shown in Figure 4.19. The 
molecular weight of it is 58000 Da. uPA is a serine protease and it has numerous functions. 
Urokinase mainly involved with degradation of extracellular matrix and stimulation of cellular 
migration processes related to cancer progression. The receptor uPAR is a 
glycosylphosphatidylinositol anchor protein. This receptor can cooperate with integrins, which 
are membrane partners to control tumor cell adhesion, migration, invasion, protease secretion 
and proliferation. According to the literature uPA helps the spread of the cancer. Cell migration 




Figure 4.20: Integrated Fluorescence of the Blood Samples for Urokinase Assay 
 
In Figure 4.20 the integrated fluorescence data for all the blood serum samples and in 









values for the blood samples. Based on the validation shown in Chapter 3 
urokinase is a protease, which defied the light switch paradigm. However, the presence of 
thousands of proteins in blood serum may complicate the situation (see chapter 8). 
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Figure 4.21: Comparison of Blood Samples for uPA 
 
 4.3.8 Study of Cathepsin B Protease Assay Data  
 




The structure of Cathepsin B (CTSB) can be seen in Figure 4.22. It is a lysosomal 
cysteine protease, which is synthesized in the rough endoplasmic reticulum and delivered to the 
lysosomal compartment. The molecular weight of Cathepsin B is 37000 Da. It is mainly involved 
in degradation of the extracellular  matrix and basement membrane, directly and indirectly. As a 
result, cathepsin B is playing an important role in cancer progression and invasion.
20,21
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Figure 4.23: Integrated Fluorescence of the Blood Samples for Cathepsin B Assay 
 
In figure 4.23 the integrated fluorescence data for all the blood serum samples and in 









the blood samples of the cancer patients are similar with a few exceptions.  Based on the 
validation shown in chapter 3, cathepsin B  is a moderately reactive protease. 
 
 
Figure 4.24: Comparison of Blood Samples for Cathepsin B 
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 4.3.9 Study of Cathepsin L Protease Assay Data  
 
Figure 4.25: Structure of Cathepsin L
5 
 
Cathepsin L, a papain-like lysosomal cysteine proteinase and its structure is shown in 
Figure 4.25. It is synthesized as a preproenzyme. The lysosome is the location to store the mature 
type of the cathepsin L. There, cathepsin L functions as an endopeptidase. The molecular weight 
of cathepsin L is 26000 Da. It plays a key role in degradation of intracellular and extracellular 
proteins. At acidic pH, cathepsin L has the ability to degrade collagen, elastin, laminin and other 
components of the basement membrane. Therefore cathepsin L is considered as a contributor in 




Figure 4.26: Integrated Fluorescence of the Blood Samples for Cathepsin L Assay 
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In Figure the 4.26 integrated fluorescence data for all blood serum samples and in Figure 








values for the 
blood samples of the cancer patients are very similar, again with a few exceptions. Based on the 




Figure 4.27: Comparison of Blood Samples for Cathepsin L




I would like to acknowledge all the collaborators, who contributed their knowledge and 
expertise towards the success of the projects on protease assays.   
 
Prof. Dr. Gary Gadbury, Department Head of the Department of Statistics, Kansas State 
University and M. Sc. Xin Sun. 
 
The analysis described in the section 4.4 has been performed by Dr. Gary Gadbury of the 
Department of Statistics, Kansas State University. The whole Analysis report will be reported in 
Appendix A. 
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 4.4 Statistical Analysis  
We did the statistical analysis of all the data collected for the lung and breast cancer 
blood samples. Statistical analyis for separate assays can be found in Appendix A. The summary 
of the statistical data analysis is shown here in Tables 4.2 and 4.3. 
 
Table 4.2: Summary of Results Comparing Stage of Disease in Breast Cancer Patients with 
the Control Condition 
 
Outcome Stage 0 Stage I Stage II Stage III Stage IV 
Cath B N N N H H 
Cath L N N N N H 
MMP1 N N N H H 
MMP2 N N N N N 
MMP3 N N N N N 
MMP7 N N H N N 
MMP9 N N N H H 
MMP13 N N N N N 
uPA N N L L L 
 
In tables 4.2 and 4.3 “N” indicates no statistical difference, “H” indicates that the 
outcome was estimated to be higher in the disease stage versus control, and “L” indicates that the 
outcome was estimated to be lower in the disease stage versus control. There were five stages 
present in breast cancer patients and three stages present in lung cancer patients. Statistical 
differences have been determined using 95% confidence intervals with a Bonferroni adjustment 
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Table 4.3: Summary of Results Comparing Stage of Disease in Lung Cancer Patients with 
the Control Condition 
 
Outcome Stage I Stage II Stage III 
Cath B N H H 
Cath L N H H 
MMP1 H H H 
MMP2 N N N 
MMP3 N N N 
MMP7 H N H 
MMP9 L L L 
MMP13 N N N 
uPA N N N 
 4.5 Discussion  
We carried out all the calibrations of the protease assays using commercially available 
enzymes in 1X PBS buffer. But when we were working with the real protease assays using blood 
serum samples, the behavior of the proteases in the blood samples were somewhat different 
compared to how they behaved in PBS buffer. For an example, as described in chapter 3, we 
have identified urokinase and MMP 9 as proteases which defying the light switch paradigm. But 
with all these blood analysis work, we achieved increasements in fluorescence of TCPP with 
both of these proteases. This observation led us into looking at the surface properties of the 
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Chapter 5 - Detection of Triple Negative Breast Cancer  
Using Protease Assays 
 5.1 Triple Negative Breast Cancer 
Triple Negative Breast Cancer (TNBC) is a subtype of breast cancer. As the name 
implies, triple negative means testing is negative for estrogen receptors (ER), progesterone 
receptors (PR) and HER2. Which means triple negative breast cancers do not have those 
biomarkers. 15-20 percent of all the breast cancer types in USA are Triple Negative.  This cancer 
type can be mostly seen with younger women, African American women, Hispanic/Latina 
women, and women who have BRCA1 mutations.
1
  
Triple Negative breast cancer is very aggressive, and usually hormonal therapy is not 
working in treating TNBC. The reason behind that is the growth of this tumor is not accelerated 




 5.2 Results of Protease Assays 
We received 10 Triple Negative breast cancer blood serum samples from The University 
of Kansas Hospital (Prof. Dr. Priyanka Sharma, MD). The protease assay analysis was done for 
all 10 blood serum samples. Results were obtained for 12 types of proteases. Seven of them are 
from the MMP family: MMP 1, MMP 2, MMP 3, MMP 7, MMP 9, MMP 11 and MMP 13. Four 
of them are from the cathepsin family: Cathepsin B, cathepsin D, cathepsin K and cathepsin L. 
Also the analysis was performed using the urokinase assay. 
The assay procedure is the same as described in section 4.1.1. 
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 5.2.1 Study of MMPs             




Figure 5.1: Matrix Metalloproteinases in Blood Serum of Triple-Negative Breast Cancer 
Patients  
 5.2.2 Study of Cathepsins and Urokinase 
 
              
 
 
Figure 5.2: Cathepsins and Urokinase Plasminogen Activator in Blood Serum of Triple-
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 5.3 Discussion 
 Whereas the blood samples that were obtained from the South Eastern Nebraska Cancer 
Center (SENCC) were comprised of all breast cancer types, the blood samples from the 
University of Kansas were exclusively Triple Negative Breast Cancers (TNBC). As anticipated, I 
found distinct differences in the expression pattern of proteases in both groups of cancer 
samples. It must be noted that the blood serum samples from TNBC patients did not have a 
control group. This limits the ability to compare protease expression patterns to a certain extent. 
It is of interest that these samples have originated in the year 2008. I did not have any problems 
to obtain meaningful results utilizing the protease assays that were developed in this thesis. 
Therefore, it is safe to assume that blood serum samples can be stored either at -80
o
C or in liquid 
nitrogen for years prior to measuring protease signatures. Considering the infrastructure 
requirements necessary for early blood tests for cancer in millions of patients, this finding must 
be regarded as very good news, because it permits the design of central testing facilities with 
very high throughput. 
 MMP 11 was not analyzed in the samples obtained from SENCC. However, MMP 11 is 
potentially of high diagnostic value for detecting triple negative breast cancers. Gli1 is an 
established oncogene that is expressed in TNBC. It enhances migration and invasion via 
upregulation of MMP 11.
3
 It is noteworthy that we did not discern a significant overexpression 
of MMP 13 in the blood serum samples obtained from SENCC, but in the group of TNBC 
patients from KUMED. There is an emerging paradigm in the recent literature that some of the 
same factors that drive epithelial–mesenchymal transition (EMT) upregulate MMP13 expression 
(e.g., TGFβ, IL1b, TNFα), indicating an association of MMP13 with invasion and metastasis.
4
  
 It was our original strategy to compare the MMP-activities with the complete histology of 
the TNBCs that will be performed by Dr. Sharma. Unfortunately, these studies have been 
delayed due to legal complications, which have arisen from the bankruptcy of NanoScale 
Corporation (a spin-off of Kansas State University). NanoScale Corporation was involved in the 
cancer endeavors of the Bossmann group from 2008 to 2012. The goal of this study is to 
verify/falsify these two pathways in patient-specific TNBC pathology, with the goal of 
developing better predictors for cancer treatment and survival. This analysis will be continued, 
but the work will have to be performed in continuation of my thesis research. 
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 MMP 9, which is a typical inflammation marker, was overexpressed in the blood serum 
of late stage breast cancer patients (states 3 and 4) from SENCC. It is of interest that MMP 9 
overexpression is apparently a hallmark of all breast cancers. Urokinase plasminogen activator 
(uPA) is mainly involved in the degradation of extracellular matrix and stimulation of cellular 
migration processes related to cancer progression. uPA is apparently involved in the progression 
of all breast cancers, disregarding of the cancer type. That also means that MMP 9 and uPA are 
suitable proteases to detect all types of breast cancers in a simple blood serum test. However, 
both proteases are highly overexpressed only in late stage breast cancers, which limits their 
usefulness. 
 The expression of MMP 1, MMP 3, and MMP 7 varies from sample to sample. In the 
samples obtained from SENCC, MMP 7 activity was significantly elevated in stage 2 breast 
cancers, whereas MMP 1 was significantly elevated in later stages (3 and 4). It is of importance 
that triple negative breast cancers are not a homogeneous group, as discussed in the introduction. 
Therefore, it is possible that several sub-groups of TNBC’s feature different protease signatures. 
My findings with MMP 1, MMP 3, and MMP 7 may be a first indication for this behavior. 
However, larger sample numbers are required to verify this assumption. These studies will be 
continued in collaboration with Prof. Dr. Sharma. 
 It should also be noted that MMP 2 expression was insignificant for all blood samples 
investigated. 
 Among the group of the cathepsins, cathepsin B was elevated in all blood serum samples 
from TNBC patients, whereas cathepsins D, L, and K were not significant.  In the group of 
samples obtained from SENCC, cathepsin B was a significant late stage breast cancer marker 
(stages 3 and 4). We will require a higher number of blood serum samples from TNBC patients 
to arrive at a statistically significant conclusion, whether cathepsin B is also elevated in some 
breast cancers types in early stages. To date, we have established that cathepsin B, together with 
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Chapter 6 - Detection of the Breast Cancer Boundary Using 
Magnetic-Nanoparticle (Fe/Fe3O4)-based Nanoplatforms for Highly 
Sensitive Fluorescence Detection of Cancer-Related Proteases 
 6.1 Introduction 
On the path of the development of the protease assay, we wanted to look into the activity 
of proteases in tumor tissue. The underlying paradigm of this research is that protease activity in 
the tumor core, boundary region, and adjacent “healthy tissue” may be significantly different to 
permit an exact elucidation of the tumor boundary. In order to perform this research, we received 
tissue samples from 12 breast cancer patients from the University of Kansas Medical Center. 
This work is performed in collaboration with Dr. Fang Fan, MD, Director, Cytopathology 
Fellowship Program. From each patient three types of tissue samples were obtained. The samples 
are described in Tables 6.1 and 6.2. 
 
Table 6.1: Tissue Samples 
No Code Type 
1 A Inside the tumor core 
2 B Boundary of the tumor 
3 C Control healthy tissue next to the tumor 
 
 














T N M 
1 3267 Ductal Negative positive positive negative I 2 1c 0 
 
2 3275 Ductal Negative positive positive negative 2 2 1c 0 
 
3 3315 Ductal Negative positive positive negative 1 2 1c 0 X 
4 3662 Ductal Negative positive positive negative II/III 3 2 2 
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5 3681 Other Negative positive positive negative 1 2 2 0 
 
6 3768 Ductal Negative positive positive negative 1 1 2 1a X 
7 3773 Ductal Negative positive positive negative 2 2 2 2 
 
8 3780 Ductal Negative positive positive negative II 3 1c 0 
 
9 3890 Ductal Negative positive negative negative 2 2 1c 1a X 
10 3922 Ductal Negative positive negative negative 2 2 2 0 X 
11 3988 Ductal Negative positive positive negative 2 3 1c 1 
 
12 4533 Ductal Positive positive negative negative II/III 3 1c 0 
 
 
In Table 6.2 the information about the tumors is summarized. 
 6.1.1 Preparation of the Samples 
All the tissue samples were prepared in a manner that is compatible with using the 
protease assay. First the tissue was cut in to very small pieces (<1 mm
3
). Then 1-5 mg of tissue 
was homogenized (mini homogenizer) for 5 min. in 600 Lof (PBS+dextran) solution 
(concentration: 10 mg of dextran in 1 mL of 1x PBS). At the end of the 5 min almost all of the 
solid was homogenized. After quick centrifugation, the homogenous supernatant was used in the 
assays.  
 6.1.2 Procedure for the Protease Assay 
The protease assay procedure that was developed in chapter 4 was further modified for 
measuring the protease activity of biospecimens.  
In a 15 mL centrifuge tube 75 L of a dispersion of nanoplatform in 1X PBS 
(concentration: 1.0 mg/mL) was given. Then 30 Lof the homogenized tissue sample (see above) 
was added. Then the total volume was increased to 3.0 mL using 1X PBS/dextran. This solution 
is a dextran solution with the concentration of 10 mg/mL. Then sonicated the tube for 5 min. and 
incubated it for 1 h at 25 
o
C. At the end of the 1 h incubation period, fluorescence measurements 
were performed. Per each sample two scans were performed. Each sample was recorded in 
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triplicates. Furthermore, assay control and tissue control were performed. The assay control 
consisted of measuring the fluorescence of the nanoplatform only without having any 
biospecimen present after the incubation period. The tissue control consisted only of the tissue 
(after the one hour incubation period) without having any nanoplatform present. Photophysical 
parameters of the experiment are excitation wavelength ( =421 nm) and the wavelength range 
of detection ( = 590 nm to 760 nm).  
Basically two peaks could be discerned in the fluorescence spectrum at 620 nm – 680 nm 
range and at 690 nm – 730 nm range. The intensity was highest at with the peak of 620 nm - 680 
nm range. As a result, only the peak occurring at 620 nm - 680 nm was considered in the 
calculations reported in this chapter. 
6.2 Results  
All 36 tissue samples were analyzed using all 12 protease assays. By analyzing the data, 
basically, we could identify three types of tumor patients. They are as follows: First, some 
patients have high protease concentrations inside the tumor core. Second, some patients have 
high protease concentrations within the boundary of the tumor. Third, some patients have high 
protease concentrations within the (presumably) healthy tissue next to the tumor. 
 6.2.1 Type 1 (High Protease Concentrations Inside the Tumor Core) 
Figure 6.1 shows an example of type 1. Here the fluorescence intensity, which 
corresponds to the tissue A, is high compared to tissue B and tissue C. In Figure 6.1 “Tissue A, B 
and C” means the (respective) tissue controls. 
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  Figure 6.1: Fluorescence Graph of Patient’s no: 3988, MMP 13 Assay  
 6.2.2 Type 2 (High Protease Concentration within the Boundary of the Tumor) 
Figure 6.2 shows an example of type 2. Here the fluorescence intensity, which 
corresponds to tissue B is high compared to tissue A and tissue C. Also in Figure 6.2 “tissue A, B 
and C” means the tissue controls. 
 
Figure 6.2: Fluorescence Graph of Patient’s no: 3315, MMP 13 Assay 
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 6.2.3 Type 3 (High Protease Concentrations within the (Presumably) Healthy 
Tissue next to the Tumor) 
Figure 6.3 shows an example of type 3. Here the fluorescence intensity, which 
corresponds to tissue C is high compared to tissue A and tissue B. In Figure 6.3 “tissue A, B and 
C” means the (respective) tissue controls. 
 
Figure 6.3: Fluorescence Graph of Patient’s no: 3768, MMP 11 Assay 
 
 6.2.4 Matrix of 12 Patients and 12 Cancer-Related Proteases  
As described above, different patients belong in different categories, based on the data. 
However, this behavior is not uniform for every protease investigated, as this becomes clear from 
Table 6.3. Then I compared all the data for 12 patients with all 12 proteases. The data has been 
tabulated in Table 6.3. In Table 6.3, A max denotes type 1 samples, the samples, which have the 
highest fluorescence increase when measuring tissue A, compared to tissue B and tissue C. B 
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max denotes type 2 samples, the samples, which have the highest fluorescence increase when 
measuring tissue B, compared to tissue A and tissue C. C max denotes type 3 samples, the 
samples, which have the highest fluorescence increase when measuring tissue C compared to 
tissues A and B. 
 



































































































































































































































































































































Just by analysing the data in the Table 6.3 it is hard to come to definite conclusions. So I 
looked into the relative protease concentrations in detail.  
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 6.2.5 Calculations Associated with Data 
 First the average of the two scans was taken. The integrated fluorescence values of the 
average data set were collected from 620 nm to 680 nm. Then the average of the triplicates per 
each sample was taken. From that final averaged data set, the integrated fluorescence value (S) 
was  taken from 620 nm to 680 nm. The integrated fluorescence values of the average data sets 
from 620 nm to 680 nm of the assay control (A) and tissue control (T) samples were recorded for 
comparison purposes. Then the difference between the two values S and T was calculated in 
order to eliminate the autofluorescence that occurs form the blood serum sample. The next step 
was to obtain the difference between (S-T) and (A). This step was performed to obtain the actual 
fluorescence increment due to the protease activity, because in the assay control there is some 
amount of TCPP that was not quenched enough to avoid a minimum of fluorescence. This 
fluorescence should not mislead us to think that it occurs due to activity of the protease.  
 
 6.3 Discussion 
It is noteworthy that the 36 tissue samples from 12 female patients, who underwent 
mastectomies, have been identified by Dr. Fang Fan as stage 2 or lower. Unfortunately, the 
survival data for these patients are not yet available from the University of Kansas Medical 
Center. It would have been very interesting to discern, whether the overexpression of any 
protease or group of protease is indicative for enhanced or decreased survival. These studies will 
be completed by my colleagues in the Bossmann group as soon as these data are available. 
Generally, the more positive the readings in Figures 6.4 to 6.15 are, the higher are the 
levels or protease expression. Levels close to zero are essentially not distinguishable from the 
controls, levels that are negative are significantly lower than their respective controls. It is our 
general paradigm that high levels of protease expression are a hallmark for aggressive cancers, 
whereas low levels are typical for benign tumors. However, we have to look at each enzyme 
individually, because it is possible that only a few proteases are significantly enhanced during 
angiogenesis and invasion. 
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 6.3.1 Study of MMP 1 Protease Assay Data  
  The statistical analysis of the results obtained using blood serum from breast and non-
small lung cancer patients that we had obtained from the Southeastern Nebraska Cancer Center 
(SNCC see chapter 4) clearly indicate that MMP 1 is a later stage cancer marker, because it was 
statistically significantly overexpressed in stage 3 and 4 cancers. In contrast, the breast cancer 
tissue samples investigated here are mainly stage 2 and lower. It is striking that the results from 
each individual patient are different. In most of the patients, the highest level of MMP 1 
expression is found in the tumor core, followed by the tumor boundary. It is noteworthy that the 
MMP 1 levels in the adjacent tissue are only elevated in three patients. These findings are 
consistent with the staging of the breast tissue samples. From these data, MMP 1 does not seem 
to be implicated in aggressive tissue invasion. However, I am aware of the fact that we have only 
investigated biospecimens from 12 patients. 
 
Figure 6.4: Integrated Fluorescence of the Tissue Samples for MMP 1 Assay 
 
In Figure 6.4 the integrated fluorescence data for all the tissue samples is shown.  
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  6.3.2 Study of MMP 2 Protease Assay Data  
 
Figure 6.5: Integrated Fluorescence of the Tissue Samples for MMP 2 Assay 
 
In Figure 6.5 the integrated fluorescence data of all the tissue samples is shown. In our 
earlier studies, MMP 2 was not identified as a significant cancer marker for stage 2 breast 
cancers in blood serum samples. Our studies here are in agreement with our earlier findings. 
Only in 6 patients MMP 2 overexpression in the tumor core and boundary region is discernible. 
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 6.3.3 Study of MMP 3 Protease Assay Data  
 
Figure 6.6: Integrated Fluorescence of the Tissue Samples for MMP 3 Assay
 
 
In Figure 6.6 the integrated fluorescence data for all the tissue samples is shown. 
Basically, the same general behavior is found as for MMP 2. MMP 3 is overexpressed only in 
the tumor cores of four patients, and in the tumor boundaries of  four patients. Note that one 
patient had only an elevated tumor core, whereas another has only increased MMP 3 in the 
boundary region. 
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 6.3.4 Study of MMP 7 Protease Assay Data  
 
Figure 6.7: Integrated Fluorescence of the Tissue Samples for MMP 7 Assay 
 
In Figure 6.7 the integrated fluorescence data for all the tissue samples is shown. The 
“picture” with MMP 7 is clearly different from MMP 1, 2, and 3. MMP 7 had been identified in 
our earlier studies (chapter 4) as marker for stage 2 breast cancers when analyzing blood serum 
samples. MMP 7 is overexpressed in the tumor cores and boundary regions of all 12 investigated 
patients. Furthermore, MMP 7 expression is highest in the boundary region of 4 cancer patients. 
Overall, the levels of MMP 7 expression found here are in excellent agreement with the results 
described in chapter 4. MMP 7 overexpression in tumor cores and boundaries seems to be 
universal in all types of breast cancer at stage 2. It is noteworthy that the expression levels of 
MMP 7 in the adjacent tissue regions are close to zero or smaller than the controls, indicating 
that MMP 7 is not majorly involved in invasion and/or angiogenesis. 
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 6.3.5 Study of MMP 9 Protease Assay Data  
 
Figure 6.8: Integrated Fluorescence of the Tissue Samples for MMP 9 Assay 
 
In Figure 6.8 the integrated fluorescence data for all the tissue samples is shown. 
Contrary to MMP 1, 2, 3, and 7, MMP 9 is a typical inflammation marker.
1
 Neutrophils, which 
are attracted by tumor
1
, are a major source of MMP 9. Therefore, it was predicted prior to my 
experiments reported here that substantial levels of MMP 9 should be found in the tissue that is 
adjacent to the tumor boundary. 
1
 The experiments summarized in Figure 6.8 provide 
experimental support for this theory: MMP 9 levels are elevated in 10 tumor cores, nine tumor 
boundaries and six adjacent tissue regions. MMP 9 production is highest in the tumor boundary 
of six patients, and in the adjacent tissue of three patients. Since it is known that inflammation 
promotes invasion in breast cancers
1
, it is my prediction that high MMP 9 levels in the boundary 
region and adjacent tissue will be a prognosticator of low survival probability. 
   116 
 
 6.3.6 Study of MMP 11 Protease Assay Data  
 
Figure 6.9: Integrated Fluorescence of the Tissue Samples for MMP 11 Assay 
 
 In Figure 6.9 the integrated fluorescence data for all the tissue samples is shown. As 
discussed in chapter 5, MMP 11 is potentially of high diagnostic value. Although most of the 
tumors that were investigated here don’t overexpress MMP 11, it is noteworthy that it is found in 
the adjacent tissue of four patients. The correlation of the patient survival data and MMP 11 
expression will show, whether this enzyme is indeed of diagnostic value. 
   117 
 
 6.3.7 Study of MMP 13 Protease Assay Data  
 
 
Figure 6.10: Integrated Fluorescence of the Tissue Samples for MMP 13 Assay 
  
 In Figure 6.10 the integrated fluorescence data for all the tissue samples is shown. I have 
also discussed in chapter 5 that there is an emerging paradigm in the recent literature that some 
of the same factors that drive epithelial–mesenchymal transition (EMT) upregulate MMP13 
expression (e.g., TGFβ, IL1b, TNFα), indicating an association of MMP13 with invasion and 
metastasis. Therefore, it is most interesting that 11 or 12 patients show upegulated MMP 13 
levels. Seven of these 11 patients show highest MMP 13 expression in the boundary region. As 
discussed above, all patients were diagnosed with stage 2 (or lower). Therefore, it is most 
interesting that MMP 13 is almost abundantly expressed in tumor cores and tumor boundaries. 
Furthermore, MMP 13 is also found in the adjacent tissue of three patients. Based on these 
findings, MMP 13 may be a good biomarker for mapping early breast tumors and to observe the 
transition between benign and cancerous lesions.  
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 6.3.8 Study of Cathepsin B Protease Assay Data 
 
Figure 6.11: Integrated Fluorescence of the Tissue Samples for Cathepsin B Assay 
 
In Figure 6.11 the integrated fluorescence data for all the tissue samples is shown. 
Cathepsin B has been identified as “late stage breast cancer marker” in our studies that are 
described in chapter 4. These findings are in agreement with this assessment. Cathepsin B is 
overexpressed only in five patients, in four of these five patients it is highest in the boundary 
regions. I anticipate that cathepsin B expression may significantly increase in stage 3 and 4 
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 6.3.9 Study of Cathepsin D Assay Data  
 
 
Figure 6.12: Integrated Fluorescence of the Tissue Samples for Cathepsin D Assay 
 
In Figure 6.12 the integrated fluorescence data for all the tissue samples is shown. With 
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 6.3.10 Study of Cathepsin K Assay Data  
 
 
Figure 6.13: Integrated Fluorescence of the Tissue Samples for Cathepsin K Assay 
 
In Figure 6.13 the integrated fluorescence data for all the tissue samples is shown. 
Cathepsin K is significantly expressed in nine patients. In only two of these samples, the 
expression level in the boundary region was higher than in the core of the tumors. Cathepsin K 
has been established in the literature as a biomarker for bone invasion
2
. Because of this reason, 
cathepsin K may be also linked to patient survival probability. 
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 6.3.11 Study of Cathepsin L Protease Assay Data  
 
 
Figure 6.14: Integrated Fluorescence of the Tissue Samples for Cathepsin L Assay 
 
In Figure 6.14 the integrated fluorescence data for all the tissue samples is shown. 
Cathepsin L is not significantly expressed in the investigated samples, with two exceptions, 
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 6.3.12 Study of Urokinase Plasminogen Activator (uPA) Assay Data  
 
 
Figure 6.15: Integrated Fluorescence of the Tissue Samples for Urokinase Assay 
 
In Figure 6.15 the integrated fluorescence data for all the tissue samples is shown. 
Urokinase plasminogen activator has been identified as biomarker for inflammation in breast 
cancer
3
. It has been also established that inflammation promotes the cancer progression. As 
summarized in Figure 6.15, uPA is overexpressed in the core and boundary regions of the tumors 
of all 12 patients. In six tumors, the cores showed highest uPA activity, whereas in the other six 
patients, the uPA activity in the boundary regions was higher. Furthermore, uPA was 
significantly expressed in the adjacent tissue regions of six patients. It has been already 
demonstrated in chapters 4 and 5 that uPA is of a principal diagnostic value in breast cancer. The 
study described here is clearly reaffirming our earlier findings. 
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Chapter 7 - IVIS Approach for the Protease Assays 
 7.1 Background 
All the analyses I have discussed in chapters 4, 5 and 6 are based on steady state 
fluorescence measurements. To get in to statistically relevant conclusions based on our results, 
we need to analyze a large number of samples from each type. Also if we need to use the 
protease assay technique in tumor screening work, we have to analyze a lot samples at the same 
time. When we need to analyze hundreds and thousands of samples, the current method we use is 
too time consuming.  
There are several reasons for this work being time consuming. First, there is only one 
cuvette holder in the spectrofluorometer (fluoromax2) that we are using. Second, we run two 
scans per each sample and we do three replicates per each sample. Third, we set the assay for 
several samples at the same time, do the incubation and get the fluorescence done. In order to 
finish the fluorescence measurements for nine samples, it takes about two hours. This includes 
the time that it takes in between transfer of the cuvettes from one to the other.  At that point, the 
time factor will also have an effect on our data. 
As an option if we can use a fluorescence plate reader that would cut off most of the 
drawbacks that I mentioned in the previous paragraph. There are 96 or 384 wells in one plate and 
we can read the fluorescence of  96/384 samples at the same time. The sample volume we need 
is clearly less than 100 L. But we need to use a higher concentration of the sample compared to 
fluoromax 2, because the optical path is different. 
Depending on the availabilities of the machines in the laboratory and with our 
collaborators, I tried the “IVIS approach” of the protease assays as the final version of the 
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 7.2 In Vivo Imaging System (IVIS) 
Currently, especially with cancer diagnostics, imaging has become a very handy tool. 
There are several categories of imaging methods. The classification depends on several factors. 




Among them, optical tomography (IVIS system) is a versatile method that can be used in 
several applications, such as life science research and drug discovery. Evaluation of structure and 
function of a living subject is the major function done by IVIS. There are several advantages of 
IVIS compared to other diagnostic methods. Major advantages are higher sensitivity, 
requirement of the less amount of cells, low noise level and non radioactivity.
2
 




Figure 7.1: IVIS Apparatus (Image Provided by Caliper Lifesciences) 
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 7.3 Analysis of Canine Blood Serum Samples  
Five canine blood serum samples were randomly selected form the set of 36 canine blood 
serum samples we have received from Prof. Dr. Mary Higginbotham, MD, Kansas State 
Veterinary Hospital.  The in-vitro protease assay was performed using the IVIS. The assay was 
carried out in transparent 96-well plates.  
100 μL of the 1x PBS (containing dextran in 10 mg in 1 mL concentration) mixture was 
pipetted in the well. To the next well 100ul of the MMP 11 nanoplatform was pipetted. Then 50 
uL of the canine serum sample was pipetted in to the same well, mixed. Likewise all the samples 
were pipetted in to the wells. control experiments were also carried out. Then the fluorescence 
detection was conducted by IVIS apparatus.  
Images were obtained by imaging the plate at exposure time 5 min., 10 min., 15min., up 
to 90 min., in 5 minutes intervals. Quantitative analysis was achieved by analyzing the 
correlation between the concentration of the protease and the intensity of the fluorescence. The 
contents of the well and well number are shown in table 7.1 and the image is shown in Fig. 7.2. 
 





A1 150 uL of 1x PBS (with dextran)  
A2 100 uL of MMP 11 nanoplatform + 50 uL of 1x PBS (with dextran) 
A3 50 uL of Sample 1 + 100 uL of 1x PBS (with dextran) 
A4 50 uL of Sample 1 + 100 uL of MMP 11 nanoplatform 
A5 50 uL of Sample 2 + 100 uL of 1x PBS (with dextran) 
A6 50 uL of Sample 2 + 100 uL of MMP 11 nanoplatform 
A7 50 uL of Sample 3 + 100 uL of 1x PBS (with dextran) 
A8 50 uL of Sample 3 + 100 uL of MMP 11 nanoplatform 
A9 50 uL of Sample 4 + 100 uL of 1x PBS (with dextran) 
A10 50 uL of Sample 4 + 100 uL of MMP 11 nanoplatform 
A11 50 uL of Sample 5 + 100 uL of 1x PBS (with dextran) 
A12 50 uL of Sample 5 + 100 uL of MMP 11 nanoplatform 
 




Figure 7.2: IVIS imaging of the Canine Serum Samples 




Figure 7.3: Increment in Fluorescence in IVIS 
 
 There is no significant increment in fluorescence with serum control samples and assay 
control sample, which is a good indication that this technique can be used for detection of 
protease activity. Consequently we can explain that the increment in fluorescence we see arises 
only due to the activity of MMP 11 protease in blood serum. Here the order of the samples 
depending on the fluorescence increment is as follows: 
Sample 5 (090450) > Sample 3 (083662) > Sample 1 (089640) > Sample 2 (090668) > Sample 4 
(085758) 
   129 
 
 
Then I carried out the fluoromax experiments to the same set of canine serum samples. 
 
 
Figure 7.4: Increment in Fluorescence using the Fluoromax 
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 Here the order of the samples depending on the fluorescence increment is as follows. 
Sample 3 (083662) > Sample 2 (090668) > Sample 1 (089640)  > Sample 5 (090450) > Sample 4 
(085758). 
 The next step was to compare the fluorescence increments of the five canine serum 
samples using both techniques (see Figure 7.5) 
 
Table 7.2:  Comparison of Integrated Fluorescence of IVIS and Fluoromax 
 
Sample No Fluoromax IVIS 
5 (090450) 2478153 408800000 
3 (083662) 2637583 329850000 
1 (089640)   2547387 316333333 
2 (090668) 2588300 274166666 




Figure 7.5: Comparison of Integrated Fluorescence of IVIS 
5 (090450), 4 (085758), 3 (083662), 2 (090668),  1 (08964) 
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The proof-of-principle experiments described in this chapter clearly demonstrate that 
fluorescence plate readers can be used to determine the activity of (cancer-related) proteases.  
The IVIS equipment proved to be sufficiently sensitive to measure protease activity in 96-well 
plates. Considering that classic fluorescence plate readers are approx. 10 times more sensitive 
than the IVIS
4
, which is configured for optical tomography on small animals, it is my prediction 
that they will be ideal for measuring protease signatures of (cancer) patients in hospitals. It is of 
importance for the implementation of the technology that has been developed in my thesis that 
the equipment required for clinical use already exists and is already in use in many clinical 
laboratories. However, due to the differences in optical path length and irradiation geometry, the 
experimental conditions for measuring protease activities will have to be optimized when using 
fluorescence plate readers. 
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Chapter 8 - Surface Properties of the Protease Assay Components  
 8.1 Introduction 
The validation of the protease assay, which is described in chapter 3, has been performed 
using commercially available proteases in PBS. The analysis, which are described in chapters 4, 
5 and 6, have been performed using proteases from biospecimens in PBS. Due to the presence of 
thousands of proteins in these biospecimens the two situations are different from each other. 
Therefore, it would be surprising if the photophysical conditions would not be influenced by the 
presence of (thousands of) proteins. This reasoning made me to look in to the aggregation of the 
components of the protease assay. 
 8.1.1 Dynamic Light Scattering 
"DLS measurements involve the analysis of the time autocorrelation function of scattered 
light as performed by a digital correlator."
1
 The method is described in detail in reference 1. The 
hydrodynamic diameters of the nanoplatforms and nanoplatform aggregates were measured 
using a ZetaPALS Zeta Potential Analyzer (Brookhaven Instruments Corporation) by 
hydrodynamic light scattering. This instrument is capable of performing routine experiments, 
which do not require elaborate calculations to obtain hydrodynamic diameters. 
 
 8.2 Dynamic Light Scattering Data 
DLS measurements have been performed for the assay probes, assay probes with 
enzymes, assay probes with blood serum, and assay probes with human tissue extracts. DLS data 
were obtained for urokinase, cathepsin D and MMP 7 assay systems, which served as model 
enzymes: one member from each protease family has been chosen. 
 8.2.1 DLS for Cathepsin D  
First, DLS measurements were performed using the nanoplatform for cathepsin D. The 
concentration of the assay probe is 0.10 mg/mL in PBS. The samples were allowed to reach an 
equilibrium for 24 h and measurements were recorded. In all the measurements shown in Figure 
8.1, the final volume in the cuvette was 3 mL. 
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Figure 8.1: DLS of Cathepsin D Assay Probe without Dextran 
 
The data summarized in Figure 8.1 clearly indicate that clustering occurs at each 
investigated concentration. The clustering is not really concentration dependent, which may be 
caused by the used algorithms, which were optimized for polymers and not for metal 
nanoparticles. In order to disperse the nanoplatforms in PBS, dextran (10 mg/mL) was used. 
Dextran caused a significant decrease in the effective diameters. Furthermore, the hydrodynamic 
diameters were now dependent on the nanoparticle concentration, which is acceptable, because it 
is indicating dynamic behavior. 
 
 
Figure 8.2: DLS of Cathepsin D Assay Probe with Dextran 
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After demonstrating the anticoagulant effect of dextran, I investigated the influence of 
three model proteases, blood serum and tissue extracts on the hydrodynamic diameters. First the 
DLS measurements were taken using only for the commercially available enzymes, blood serum 
and tissue extracts in order to obtain reference data. 
 
 






As shown in Figure 8.3, cathepsin D forms modest clusters with itself, which are only 
mildly concentration-dependent.   
 
 
Figure 8.4: DLS for Canine Blood Serum  
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(sample 070001, obtained from the Kansas State Veterinary Clinic, Dr. Mary 
Higginbotham, DVM) 
Figure 8.4 clearly shows that extensive clustering occurs in PBS-diluted blood serum. 
The resulting clusters have a hydrodynamic diameter from 400-520nm, depending on the 
concentration of blood serum in PBS. 
Tissue extract 003773 A (tumor core), B (tumor boundary) and C (presumably healthy 
tissue) types were used. 
 
 
Figure 8.5: DLS for Tissue Extracts from the Core of the Tumor (Tissue extract 003773 A)  
 
 
Figure 8.6: DLS for Tissue Extracts from the Boundary of the Tumor (Tissue extract 
003773 B) 
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Figure 8.7: DLS for Tissue Extracts from the Presumably Healthy Tissue (Tissue extract 
003773 C) 
 
It is noteworthy that the concentration dependences of the dynamic light scattering of 
tissue extracts from the tumor core, boundary region and adjacent tissue in 1X PBS were 
remarkably different. At least for patient 003773, the biospecimens from tumor core, boundary 
region and adjacent tissue permit a clear differentiation. This led to the conclusion that there are 
differences in protein identity and, possibly, concentration in all three samples. However, since 
thousands of different proteins are present in all three samples, more detailed conclusions are 
impossible. However, it is important to remember that all three environments are clearly 
different from 1X PBS containing dextran. Therefore, a straightforward comparison of the 
calibration/validation results described in chapter 3 and the results obtained using biospecimens 
cannot be drawn. Therefore, in chapter 6, we have compared the relative intensities of all three 
samples with the probe control.  
 
Then DLS measurements were performed for the Cathepsin D assay probe. 
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Figure 8.8: DLS for Cathepsin D Assay Probe 
 
The lowest effective diameter was obtained with 50 Lof the assay probe (nanoplatform 
for cathepsin D) from the concentration of 1 mg/mL,  10 times diluted, in 1X PBS. It was 
selected for the next experiments. With increasing concentration, extensive clustering of the 
nanoplatform occurs in 1X PBS. 
Then to 50 L of the cathepsin D assay probe in 3mL of 1X PBS, the enzyme cathepsin 
D was added to observe the effect of the enzyme on the clustering of the nanoplatform. 
 
 
Figure 8.9: DLS for Cathepsin D Assay Probe 50 uL and Cathepsin D Enzyme  
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As it can be seen from Figure 8.9, the presence of cathepsin D increases the 
hydrodynamic diameter of the nanoplatforms for cathepsin D in PBS. Therefore, we assume that 
aggregates between the enzymes and the nanoplatform occur. At higher concentration, the 
consensus sequence for cathepsin D is cleaved faster, which leads to a partial deaggregation. 
Then in to 50 uL of the cathepsin D assay probe blood serum was added. 
 
 
Figure 8.10: DLS for Cathepsin D Assay Probe 50 uL and Blood Serum (091330) 
 
It is apparent that the clustering observed for the blood serum sample alone (see Figure 
8.4) can be seen here as well. It is safe to assume that the numerous proteins in blood serum 
define the environment that is present when the nanoassay is active. 
 
Then in to 50 uL of the cathepsin D assay probe tissue extract was added. 
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Figure 8.11: DLS for Cathepsin D Assay Probe 50 uL and Tissue Extract (003267B) 
 
Although the data summarized in Figure 8.11 show oscillation of the hydrodynamic 
diameters, it can, nevertheless, be concluded that the proteins from the tissue extract define the 
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 8.2.2 DLS for Urokinase 
Second, DLS measurements were performed using the urokinase assay probe. 
Concentration of the assay probe is 1 mg/mL, 10 times diluted with 1X PBS. Measurements 
were taken 24 h after the preparation. In all the measurements the final volume in the cuvette is 3 
ml. 
First of all, the DLS measurements were carried out using only the urokinase enzyme. 
 
 
Figure 8.12: DLS of Urokinase Enzyme  
 




was used. It 
showed a modest tendency to form clusters at higher concentrations. 
 
 
Figure 8.13: DLS for Urokinase Assay Probe 
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As it shows lowest effective diameter with 50 L of the assay probe from the 
concentration of 1 mg/mL 10 times diluted, it was selected for the next experiments. It is 
noteworthy that the nanoplatform for urokinase detection shows strong clustering, which reaches 
a plateau after 300 uL. 
Then to 50 L of the urokinase assay probe, urokinase plasimogen activator was added in 
increasing the volume of it.  
 
 
Figure 8.14: DLS for Urokinase Assay Probe 50 uL and Urokinase Enzyme 
 
It is remarkable that the presence of urokinase plasminogen activator is able to suppress 
the aggregation of the nanoplatform designed for measuring this protease. 
 
Then in to 50 uL of the urokinase assay probe blood serum was added.  
 
Figure 8.15: DLS for Urokinase Assay Probe 50 ul and Blood Serum (091330) 
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Then to 50 uL of the urokinase assay probe, tissue extract was added in increasing the 
volume of it. 
 
 
Figure 8.16: DLS for Urokinase Assay Probe 50 uL and Tissue Extract (003780B) 
 
It is noteworthy that the mixture of the nanoplatform for urokinase detection and tissue 
extract showed different hydrodynamic diameters as function of tissue extract concentration than 
the system consisting of the nanoplatform for cathepsin D detection and tissue extract. This 
finding reaffirms our earlier paradigm that each system has different biophysical properties, and 
that comparisons should be made between biospecimens of the same kind (e.g. tissue samples 
from core, boundary region and adjacent tissue). 
 8.2.3 DLS for MMP 7 
Third, DLS measurements were performed using the MMP 7 assay probe. Concentration 
of the assay probe is 1 mg/mL, 10 times diluted with 1X PBS. Measurements were taken after 24 
hours after the preparation. With all the measurements the final volume in the cuvette is 3 mL. 
First of all, the DLS measurements were carried out using only the MMP 7 enzyme. 
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Figure 8.17: DLS of MMP 7 Enzyme - Note that the Light Scattering at 0 uL MMP7 added 
arises from dextran. 
 




was used. It shows, like the 
other two studied proteases, a modest tendency towards clustering at increasing concentration. 
 
Figure 8.18: DLS for MMP 7 Assay Probe 
 
The nanoplatform for MMP 7 detection shows strong clustering. The formation of 
aggregates increased with increasing concentration until a plateau region at 250 L was reached. 
As it shows lowest effective diameter with 25 L of the assay probe from the concentration of 1 
mg/ mL 10 time diluted. It was selected for the next experiments.  
Then to 25 L of the MMP 7 assay probe, the MMP 7 enzyme was added. 
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Figure 8.19: DLS for MMP 7 Assay Probe 25 uL and MMP 7 Enzyme 
There is a significant decrease in hydrodynamic diameter when MMP 7 is present, 
compared to the aggregation behavior of the nanoplatform for MMP 7 in 1X PBS in the absence 
of the enzyme. Then  to 25 L of the MMP 7 assay probe blood serum was added. 
 
 
Figure 8.20: DLS for MMP 7 Assay Probe 25 uL and Blood Serum (090668) 
 
Interestingly, there is only a slight increase in the observed hydrodynamic diameter, 
which is again remarkably different from the observed experimental data in the case of blood 
serum with the nanoplatforms for cathepsin D and urokinase plasminogen activator. Then to 25 
uL of the MMP 7 assay probe tissue extract was added. 
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Figure 8.21: DLS for MMP 7 Assay Probe 25 uL and Tissue Extract (003267B) 
The hydrodynamic diameters in this system were somewhat similar to earlier systems, in 
which tissue extract was present. Our conclusion is that the biophysical properties in this very 

















   147 
 
 8.4 Discussion 
I have studied the main hydrodynamic diameters in a series of systems (A: proteases 
(cathepsin D, urokinase plasminogen activator and MMP7); B: nanoplatforms for protease 
detection (cathepsin D, urokinase plasminogen activator, MMP7); C: biospecimens (blood serum 
and tissue extracts), as well as combinations thereof. All measurements have been performed at 
defined concentrations and temperature (298 K) in 1X PBS (sterilized and filtered). 
A: All three enzymes showed, to various degrees, concentration dependent clustering. 
B: All three nanoplatforms showed strong clustering. The resulting supramolecular 
structures feature hydrodynamic diameters in the range of 500 to 1000nm. Adding the respective 
enzymes led to partial dispersion of the supramolecular structures. These conditions are very 
similar to those during the calibration and validation of the nanoplatform. It is of importance that 
each nanoplatform shows a different tendency towards the formation of clusters in PBS and that 
each  mixture of nanoplatform and respective enzyme behaves differently. 
C: Both investigated biospecimens in 1X PBS showed large hydrodynamic diameters, 
due to the presence of thousands of peptides in these mixtures. The light scattering properties of 
blood serum in 1X PBS were strongly, but again differently, affected by the presence of 
nanoplatforms for protease detection. Tissue extracts were less affected by the presence of 
nanoplatforms, but tissue extracts from different positions (tumor core, boundary region and 
presumably healthy tissue adjacent to the tumor) were quite different with respect to each other. 
Based on my dynamic light scattering experiments, we have arrived at the conclusion that 
kinetic measurements for the determination of protease activity can only be compared if the 
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Chapter 9 - Conclusion 
Cancer related proteases including Matrix Metalloproteinases (MMPs), Tissue Serine 
Proteases (uPA), and Cathepsins (CTS’s) have the potential to become reliable biomarkers for 
the detection of solid tumors in early stages. We have successfully designed and developed a 
magnetic-nanoparticle (Fe/Fe3O4) - based Nanoplatforms (Light - Switch) for highly sensitive 
fluorescence detection of cancer-related proteases. Monitoring the protease signature of the 
patient provides the basic concept for early cancer detection. The nanoplatform consist of 
dopamine-coated Fe/Fe3O4 core/shell nanoparticles to which the fluorescent dye TCPP 
(Tetrakis(4-carboxyphenyl)porphyrin) and the FRET-acceptor (Förster Resonance Energy 
Transfer) cyanine 5.5 are co-attached. The consensus sequences between TCPP and the central 
nanoparticle are hydrolytically cleaved by their respective proteases, which are highly selective. 
Due to the very small experimental error, the detection of protease concentrations down 




 is achieved for MMP1, MMP2, MMP3, MMP7, MMP9, MMP11, MMP13, 
uPA, CTS B, CTS D, CTS L, and CTS K after 1h of incubation. These nanoplatforms are 
sensitive enough for future use in routine clinical diagnostics for the early detection of solid 
tumours and enable the recording of “protease signatures”, which may be patient- or tumor-
specific. 
Based on our calibration results, we have found three principal groups for the protease 
activities. The group of proteases that causes the fastest increase of fluorescence intensity upon 
enzyme activation of their respective nanoplatforms is comprised of  MMP7, MMP11, MMP13, 
and cathepsin L. The nanoplatforms for measuring MMP1, MMP2, MMP3, cathepsin B and 
cathepsin D show less pronounced fluorescence increases. The group comprising the 
nanoplatforms designed for measuring uPA, MMP9 and cathepsin K interestingly shows a 
decrease and not an increase. 
We identified several protease combinations, which can be used to detect different stages 
of the breast and lung cancer as different from the control conditions. With breast cancer, stage 
IV can be detected using a panel consisting of Cathepsin B, Cathepsin L, MMP 1, MMP 9 and 
urokinase proteases. Stage III can be detected with a panel consisting of Cathepsin B, MMP 1, 
MMP 9 and urokinase proteases. Stage II can be detected with MMP 7 and urokinase proteases. 
With lung cancer, Stage III can be detected using Cathepsin B, Cathepsin L, MMP 1, MMP 7 
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and MMP 9 proteases. Stage II can be detected using Cathepsin B, Cathepsin L, MMP 1 and 
MMP 9 proteases. Stage I can be detected using MMP 1, MMP 7 and MMP 9 proteases. 
We recognized some other protease combinations, which have the ability to detect triple 
negative breast cancer (TNBC).  MMP 11 is potentially of high diagnostic value for detecting 
TNBC. There is a significant overexpression of MMP 13 with TNBC. Cathepsin B was elevated 
with TNBC. MMP 9 overexpression is apparently a hallmark of all breast cancers. There can be 
several sub-groups of TNBC’s feature different protease signatures. We require a higher number 
of blood serum samples from TNBC patients to arrive at a statistically significant conclusion. To 
date, we have established that cathepsin B, together with MMP1 and MMP9 is a reliable late-
stage marker for breast cancer. 
Regarding the data we obtained from breast cancer tissue analysis,  MMP 1 does not 
seem to be implicated in aggressive tissue invasion. MMP 2 and MMP 3 were not identified as a 
significant cancer marker. MMP 7 overexpression in tumor cores and boundaries seems to be 
universal in all types of breast cancer at stage 2. High MMP 9 levels in the boundary region and 
adjacent tissue will be a prognosticator of low survival probability. MMP 13 may be a good 
biomarker for mapping early breast tumors and to observe the transition between benign and 
cancerous lesions. 
From the data of hydrodynamic parameters that we obtained several conclusions can be 
made. Enzymes show, to various degrees, concentration dependent clustering. Nanoplatforms 
show strong clustering. Biospecimens in 1X PBS show large hydrodynamic diameters, due to the 
presence of thousands of peptides in these mixtures. Therefore, kinetic measurements for the 
determination of protease activity can only be compared if the medium, in which the 
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H-NMR of 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-benzo[e]indol-3-ium 
(Varian, 400 MHz)








H-NMR of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate 
(Varian, 400 MHz)
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Appendix B - Mass Spectra 
 
 
Figure 9.5 : Mass Spectrum (MALDI-TOF) of consensus sequence for MMP 13 











Figure 9.6 : Mass Spectrum (MALDI-TOF) of consensus sequence for uPA 
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Figure 9.7: Mass Spectrum (electrospray) of TCPP-labeled consensus sequence for 









Figure 9.8 : Mass Spectrum (electrospray) of 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-
benzo[e]indol-3-ium. Calculated mass for 3-(5-carboxypentyl)-1,1,2-trimethyl-1H-
benzo[e]indol-3-ium is 309.1. 





Figure 9.9 : Mass Spectrum (electrospray) of 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-
yl)butane-1-sulfonate. Calculated mass for 4-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-
yl)butane-1-sulfonate is 331.12. 
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Figure 9.10 : Mass Spectrum (electrospray) of Cyanine 5.5. Calculated mass for Cyanine 
5.5 is 704.3. 






Figure 9.11 : Mass Spectrum (electrospray) of (4-carboxyphenyl)porphyrin (TCPP). 
Calculated mass for (4-carboxyphenyl)porphyrin (TCPP) is 790.2. 
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Appendix C - Statistical Analysis Report 
Analysis of Data for the Project: Protease-based Cancer Diagnostics     
0. Summary of Results 
Tables 0.BC and 0.LC summarize findings in the analysis of the data for the KBA 
project. Table 0.BC summarizes results that compare the stage of disease in breast cancer (BC) 
patients with the control condition. There were five stages of disease present in BC patients.  
Table 0.LC summarizes results that compare the stage of disease in non-small lung cancer (LC) 
patients with the control condition. There were three stages of disease present in LC patients.  
An “N” indicates that no statistical difference was seen between that stage of disease and 
the control condition. An “H” means that a difference was seen and that the mean value of the 
outcome variable was higher in the disease stage than the control stage. An “L” means that a 
difference was seen and that the mean value of the outcome variable was lower in the disease 
stage than the control stage. Statistical differences were determined using 95% confidence 
intervals with a Bonferroni adjustment within each separate analysis. Thus, five comparisons 
were made in each analysis of BC data and three comparisons in each analysis of LC data. 
 
Table 0.BC: Summary of results comparing stage of disease in BC patients with the control 
condition. “N” indicates no statistical difference, “H” indicates that the outcome was 
estimated to be higher in the disease stage versus control, and “L” indicates that the 
outcome was estimated to be lower in the disease stage versus control.  
Outcome Stage 0 Stage I Stage II Stage III Stage IV 
Cath B N N N H H 
Cath L N N N N H 
MMP1 N N N H H 
MMP2 N N N N N 
MMP3 N N N N N 
MMP7 N N H N N 
MMP9 N N N H H 
MMP13 N N N N N 
uPA N N L L L 
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Table 0.LC: Similar to Table 0.BC except for the analysis of LC data versus controls.  
Outcome Stage I Stage II Stage III 
Cath B N H H 
Cath L N H H 
MMP1 H H H 
MMP2 N N N 
MMP3 N N N 
MMP7 H N H 
MMP9 L L L 
MMP13 N N N 
uPA N N N 
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1. Overview of Data and Approach to Analyses 
Data for 20 breast cancer (BC) patients, 12 non small lung cancer (LC) patients, and 12 
control patients were analyzed. The 20 BC patients were categorized into five stages: stage 0 (2 
patients), stage I (2 patients), stage II (3 patients), stage III (6 patients), and stage IV (7 patients).  
 The LC patients were categorized into three stages: stage I (1 patient), stage II (6 
patients), and stage III (5 patients). There were no stage 0 or stage IV LC patients.  
A covariate, Age, was also recorded. The BC patients tended to be older than the control 
patients. The age of BC patients ranged from 36 to 81 years of age with an average age of 57.4 
years. The control patients ranged in age from 26 to 62 years with an average age of 42.9 years. 
LC patients had a similar age distribution with control patients. The age of LC patients ranged 
from 27 to 63 years with a mean of 46.2 years.  
For each patient, 9 primary outcome variables were measured: Cath B, Cath L, MMP1, 
MMP2, MMP3, MMP7, MMP9, MMP13, and uPA. A sample was obtained from each patient 
and the measurement process for the outcome variables was carried out independently three 
times. There were two BC patients with the same label, B6. These patients were subject codes 
NS2011-013B and NS2011-014B. The latter was given the label B6a. This particular labeling 
code will be used as a “Patient” variable in a repeated measures analysis. 
Each outcome variable will be modeled separately. In each model, the outcome variable 
(or a transformation of it) will be the response and explanatory variables will be Age (if 
significant) Stage of disease (including control), and Patient as a random effect. A test for an Age 
– Stage interaction will also be considered. BC and LC patients will be analyzed separately along 
with the control patients. Of primary interest is a contrast comparing stage of disease versus 
control. Approximate t-distribution based (with Satterthwaite degrees of freedom) interval 
estimates of contrasts along with P-values for a test of significance will be reported. Interval 
estimates will have 95% confidence and include a separate Bonferroni adjustment for each 
analysis (i.e., 5 contrasts for BC data and 3 for LC data).  All analyses were conducted using R 
(www.r-project.org) and SAS (The SAS Institute, Cary, NC). These data are observational and 
samples are relatively small. Whether results that follow extend to a larger population will 
depend on how representative these patients are of a broader target population. 
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2.  Analysis of Cath B (cathepsin B) 
2A) BC patients versus Control 
 There were three measurements that were detected as outliers and removed from the 
analysis. These were the third measurement for patient NS2011-010C, and the first and second 
measurements for patient NS2011-006B. Thus there were a total of 93 Cath B observations that 
were analyzed in a repeated measures model. Diagnostics suggested transforming the Cath B 
measurements by natural logarithm transformation. After outlier removal and transformation, 
diagnostic plots on both residuals and random effects looked reasonable to proceed with 
analyses. The age of patient was not significant (P=0.75) and, so, was not considered further. 
Results of Cath B for BC patients: 
 Table 1 shows estimated contrasts on the log-scale. Each contrast compares a stage of the 
disease to the control condition. Confidence intervals not covering zero are considered showing a 
“statistically significant” difference between that stage of disease and the controls. Table 2 shows 
estimates of contrasts on the original scale of measurement. These are then estimates of 
multiplicative effects of a disease stage versus controls. A confidence interval not covering 1 is 
considered statistically significant.  
 
Table 1: Estimates of contrasts. The Label column states the comparison being tested. The other 
columns are, respectively, the estimate of the contrast, a P-value for a two-tailed test of the contrast 
equaling zero, and the lower and upper 95% confidence interval estimates with Bonferroni 
adjustment.   
  Label Estimate P-value  Lower Upper 
0   minus C -0.1492 0.6855  -1.1490 0.8505 
I   minus C  -0.5757 0.1243 -1.5745  0.4231 
II  minus C  0.1970   0.5273 -0.6472  1.0412 
III minus C  0.9487  0.0004  0.2948  1.6026 
IV  minus C   1.2644 <.0001   0.6424  1.8864 
Table 2: Similar to Table 1 but on the original scale of measurement. Only estimates are shown.  
  Label  Estimate Lower  Upper  
0   minus C   0.8614  0.3168  2.3418 
I   minus C   0.5623   0.2071  1.5269 
II  minus C   1.2177   0.5235  2.8327 
III minus C   2.5823   1.3427  4.9660 
IV  minus C   3.5410   1.9010  6.5958 
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Discussion of Cath B BC analysis: 
 Tables 1 and 2 suggest that stage III can be detected as different from the control 
condition using the cathepsin B measurements. Table 2, in particular, estimates that the mean 
cathepsin B value to be approximately 2.58 times greater in stage III patients versus control 
patients. This value could be as small as 1.34 times or as large as 4.97 times at 95 % confidence 
(adjusted for simultaneous estimates).  These values are larger when comparing stage IV patients 
with controls.  
 
2B) LC patients versus Control 
 The outlying third measurement for control patient NS2011-010C was removed as for the 
BC analysis.  Thus there were a total of 71 cathepsin observations that were analyzed. 
Diagnostics again suggested transforming the cathepsin measurements by natural logarithm 
transformation. After outlier removal and transformation, diagnostic plots on both residuals and 
random effects showed a possible influential observation due to patient NS2011-019L. This 
stage II cancer patient had cathepsin B values considerably lower than the values for other stage 
II patients. Analyses were first conducted using the data that included this patient and then using 
data that omitted this patient. As before, age was not significant in the model and not considered 
further.  
Results of Cath B for LC patients: 
Using all of the data except the third measurement for control patient NS2011-010C, there were 
no significant differences detected among the stages of disease and the control condition. An 
overall test of significance of staging in the model gave an approximate P-value equal to 0.28.  
As a secondary analysis, data for patient NS2011-019L were omitted from analyses resulting in a 
total of 68 observations for analysis. Age remained not significant with this change. Results 
similar to those described for Table 1 are shown below for the lung cancer data in Table 3. Table 
4 shows interval estimates on the original scale and are results analogous to those in Table 2 for 
the BC data.  
 
Table 3: Estimates of contrasts comparing stage of disease and controls. Column descriptions are 
those as described for Table 1. 
 Label Estimate P-value  Lower   Upper 
I   minus C  -0.9971 0.0249   -2.0698    0.0755 
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II  minus C       0.6024    0.0094    0.0538   1.1510 
III minus C     0.6515   0.0055   0.1029   1.2000 
Table 4: Estimates of contrasts on original scale. Effects are thus multiplicative. 
 Label Estimate Lower Upper 
I   minus  C   0.3689 0.1262  1.0789 
II  minus C   1.8265  1.0551   3.1620 
III minus C   1.9183  1.1081   3.3209 
Discussion of Cath B LC analysis: 
 Results suggest some significant differences between the control group and stage II and 
III cancer patients, after a multiple testing adjustment is applied. For example, Table 4 estimates 
that stage II patients, on average, will have approximately 1.86 times higher cathepsin B values 
versus controls. The uncertainty in this value ranges from 1.06 to 3.16. Again, these results hinge 
on omitting the data representing the stage II patient, NS2011-019L. Including this patient in the 
analyses eliminates any statistical significance due to the unusually low values of cathepsin B in 
this patient versus the other five stage II patients in the data set.  
 
3. Analysis of Cath L Data 
3A) BC patients versus Control 
 Control patient NS2011-016C was an extreme outlier in all models considered and was 
dropped from the analysis. The measurements for Cath L were not unusual, but two 
measurements for this patient were high and the other much lower. Thus all three residuals for 
this patient were extreme. Thus 93 measurements were analyzed. A natural logarithm of Cath L 
was used as the outcome variable. Age was only marginally significant (P=0.084) and, thus, not 
used in the model. 
Results of Cath L for BC Patients 
 Table 5 shows estimated contrasts on the log-scale. Each contrast compares a stage of the 
disease to the control condition. Confidence intervals not covering zero are considered showing a 
“statistically significant” difference between that stage of disease and the controls. Table 6 shows 
estimates of contrasts on the original scale of measurement. These are then estimates of 
multiplicative effects of a disease stage versus controls. A confidence interval not covering 1 is 
considered statistically significant. 
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Table 5: Estimates of contrasts comparing stage of disease and controls. Column descriptions are 
those as described for Table 1. 
Label Estimate P-value Lower Upper 
0   minus C 0.2230 0.4496  -0.5761 1.0222 
I   minus C 0.7882 0.0110  -0.0110 1.5874 
II  minus C 0.2035 0.4158  -0.4736 0.8807 
III minus C 0.4269 0.0338  -0.1007 0.9546 
IV  minus C 0.6472 0.0013   0.1446 1.1499 
Table 6: Similar to Table 5 but on the original scale of measurement.       
Label Estimate Lower Upper 
0   minus C 1.2499 0.5621 2.7793 
I   minus C 2.1994 0.9891 4.8907 
II  minus C 1.2257 0.6228 2.4125 
III minus C 1.5326 0.9042 2.5975 
IV  minus C 1.9102 1.1556 3.1578 
Discussion of Cath L BC analysis: 
 Tables 5 and 6 suggest that stage IV can be detected as different from the control 
condition using the Cath L measurements. Table 6, in particular, estimates that the mean Cath L 
value to be approximately 1.91 times greater in stage IV patients versus control patients. This 
value could be as small as 1.16 times or as large as 3.16 times at 95 % confidence (adjusted for 
simultaneous estimates).   
 
3B) LC Patients versus Control 
 Control patient NS2011-016C was again removed from the data to be analyzed. Thus 69 
measurements were analyzed. A natural logarithm of Cath L was used as the outcome variable. 
Age was not significant (P=0.671) and, thus, not used in the model.  
Results of Cath L for LC Patients 
 Results on the log-scale are given in Table 7 and results on the original scale are given in 
Table 8. Only three contrasts were estimated since data for only three LC stages were available. 
 
Table 7: Estimates of contrasts for Cath L LC patients. Confidence intervals are 95% with 
Bonferroni adjustment. Columns are as given in Table 1.  
Label Estimate P-value Lower Upper 
I   minus C 0.4823 0.2650 -0.6073 1.5719 
II  minus C 0.6590 0.0039  0.1296 1.1885 
III minus C 0.8412 0.0008  0.2786 1.4039 
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Table 8: Similar to Table 7 but on the original scale. 
Label Estimate Lower Upper 
I   minus C 1.6198 0.5447 4.8175 
II  minus C 1.9329 1.1382 3.2826 
III minus C 2.3192 1.3210 4.0717 
Discussion of Cath L LC analysis: 
 Tables 7 and 8 suggest that stage II and III can be detected as different from the control 
condition using the Cath L measurements for LC patients. Table 8, for example, estimates that 
the mean Cath L value to be approximately 2.31 times greater in stage III patients versus control 
patients. This value could be as small as 1.32 times or as large as 4.07 times at 95 % confidence 
(adjusted for simultaneous estimates).   
 
4. Analysis of MMP1 Data 
4A) BC Patients versus Control: 
 There were no unusual observations and no transformation was indicated necessary. Thus 
96 measurements were analyzed. Age was not significant (P=0.646) and, thus, not used in the 
model. The largest residuals in the final model were attributed to two of the measurements for 
control patient NS2011-012C, but they were not extreme enough to warrant any removal or 
modification of these measurements. So all measurement for NS2011-012C were used. 
Results of MMP1 for BC Patients 
 Table 9 shows estimated contrasts on the original scale (i.e., no transformation was used 
for this analysis). Each contrast compares a stage of the disease to the control condition. 
Confidence intervals not covering zero are considered showing a “statistically significant” 
difference between that stage of disease and the controls.  
 
Table 9: Estimates of contrasts for MMP1 BC patients. Confidence intervals are 95% with 
Bonferroni adjustment and reported on the original scale of measurement. Columns are as given in 
Table 1.  
Label Estimate P-value Lower Upper 
0   minus C    -0.0878 0.4816    -0.4255 0.2499 
I   minus C 0.3094 0.0174    -0.0284 0.6471 
II  minus C 0.2624 0.0170    -0.0230 0.5479 
III minus C 0.3481 0.0001     0.1270 0.5692 
IV  minus C 0.2945 0.0006     0.0842 0.5048 
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Discussion of MMP1 BC analysis: 
 Table 9 suggests that stage III and IV can be detected as different from the control 
condition using the MMP1 measurements. Note, though, that the P-value is significant at a 
nominal 0.05 level in a comparison of stage I condition versus the control condition. So one 
could argue that the MMP1 measurement is sensitive to a stage I versus control with some 
marginal statistical significance; however, the P-value does not attain the threshold of 
significance after a Bonferroni adjustment for 5 simultaneous tests (this threshold is 0.01).  
 
4B) LC Patients versus Control 
 Age was not significant (P=0.946) and, thus, not used in the model. There were some 
marginal outliers but these were not removed from the analysis. Data provided some indication 
that a logarithm transformation might be necessary. Analyses were done with and without this 
transformation and yielded the same results in terms of statistical significance. Thus, no 
transformation was done to be consistent with the MMP1 analysis for the BC data in section 4A.  
Results of MMP1 for LC Patients 
 Results are given in Table 10 and are on the original scale. Only three contrasts were 
estimated since data for only three LC stages were available. 
 
Table 10: Estimates and tests of contrasts on the original scale. Interval estimates are with 95% 
confidence after Bonferroni adjustment for three intervals. 
Label Estimate P-value Lower Upper 
I   minus C 0.5993 0.0004 0.2266 0.9719 
II  minus C 0.4202 <.0001 0.2411 0.5992 
III minus C 0.4889 <.0001 0.2983 0.6795 
Discussion of MMP1 LC analysis: 
 Table 10 suggests that stages I, II, and III in the LC data can be detected as different from 
the control condition using the MMP1 measurements. For example, the mean stage I level of 
MMP1 is estimated to be about 0.6 units higher in LC patients versus control. 
 
5. Analysis of MMP2 Data 
5A) BC Patients versus Control 
 The third measurement for subject NS2011-023B was an outlier and removed from the 
data set. Diagnostics provided some evidence of a need for transformation, though it was not 
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strong. On the original scale of measurement, however, there was some evidence of a significant 
Age-Staging interaction though Age by itself was not significant. A natural logarithm 
transformation improved the looks of diagnostic plots and removed the significance of the Age-
Staging interaction. Age itself was also not significant on the log scale (P=0.342) and, so, was 
not used in the model. A total of 95 observations were analyzed.  
Results and Discussion of MMP2 for BC Patients: 
 Results are given in Table 11 for the log-scale and Table 12 for the original scale. 
Confidence intervals not covering zero in Table 11 are significant and intervals not covering one 
in Table 12 are significant after the Bonferroni adjustment. As can be seen, the MMP2 
measurement does not detect any of the stages as different from control. The marginal 
significance seen in some P-values is likely to be due to random chance. A P-value equal to 
0.0476 is not significant after adjustment for multiple testing. 
 
Table 11: Estimates of contrasts comparing stage of disease and controls. Column descriptions are 
those as described for Table 1. 
Label Estimate P-value Lower Upper 
0   minus C -0.2887 0.0558 -0.6871 0.1097 
I   minus C  0.2997 0.0476 -0.0987 0.6981 
II  minus C  0.1997 0.1143 -0.1371 0.5365 
III minus C  0.0742 0.4416 -0.1866 0.3350 
IV  minus C  0.1404 0.1311 -0.1077 0.3885 
Table 12: Similar to Table 11 but on the original scale. Only interval estimates are given. Estimates 
are on a multiplicative scale.  
Label Estimate Lower Upper 
0   minus C 0.7492 0.5030 1.1159 
I   minus C 1.3494 0.9060 2.0099 
II  minus C 1.2210 0.8718 1.7100 
III minus C 1.0770 0.8298 1.3980 
IV  minus C 1.1507 0.8979 1.4747 
 
5B) LC Patients versus Control 
 There were no outliers detected in these data, so a total of 72 observations were analyzed. 
Diagnostics did not suggest a transformation; however, a natural logarithm did not alter 
diagnostic plots to any large extent. So it was decided to use a natural logarithm transformation 
   172 
 
on the MMP2 outcome variable to remain consistent with the above MMP2 analysis for BC 
patients. Age was not significant in the model (P = 0.154). 
Results and Discussion of MMP2 for LC Patients: 
 Results are reported in Table 13 for the log-scale and in Table 14 for the original scale. 
The data do not detect any significant differences between stage of disease and control. 
 
Table 13: Estimates of contrasts comparing stage of disease and controls on the log-scale. Column 
descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
  I   minus C 0.4058 0.0660 -0.1363 0.9479 
 II   minus C 0.0083 0.9359 -0.2522 0.2686 
III   minus C 0.1389 0.2097 -0.1383 0.4161 
Table 14: Similar to Table 13 but on the original scale. Only interval estimates are given. Estimates 
are on a multiplicative scale. 
    Label Estimate Lower Upper 
   I    minus C 1.5005 0.8725 2.5806 
  II    minus C 1.0083 0.7770 1.3083 
 III    minus C  1.1490 0.8707 1.5162 
 
6. Analysis of MMP3 Data 
6A) BC Patients versus Control 
 There did not seem to be any required transformation of the MMP3 outcome variable for 
this analysis. The third measurement for subject NS2011-001B (Stage 0 BC patient) and the third 
measurement for subject NS2011-004C (control patient) were identified as outliers and removed 
from the analysis. Age was not significant (P = 0.225) in the model. A total of 94 observations 
were analyzed.  
Results and Discussion of MMP3 for BC Patients: 
Results are reported in Table 15 for the original scale of data since no transformations were 
required before analysis. The data do not detect any significant differences between stage of 
disease and control. All P-values are large and all intervals cover zero. 
 
Table 15: Estimates of contrasts comparing stage of disease and controls on the original scale. 
Column descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
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0   minus C 0.0789 0.8397 -0.9806 1.1384 
I   minus C 0.2550 0.5145 -0.8042 1.3142 
II  minus C 0.0737 0.8232 -0.8215 0.9688 
III minus C -0.1481 0.5628 -0.8415 0.5453 
IV  minus C 0.1746 0.4737 -0.4850 0.8342 
 
6B) LC Patients versus Control 
 Again, there did not seem to be any required transformation of the MMP3 outcome 
variable for this analysis. The third measurement for subject NS2011-004C (control patient) was 
again removed from analysis as an outlier as it was for the BC data. Age was not significant (P = 
0.466) in the model. Data for stage II LC patient NS2011-019L seemed to produce slight 
outlying residuals in the fitted model, but it was decided that the data for this patient be left in the 
analysis. A total of 71 observations were analyzed.  
Results and Discussion of MMP3 for LC Patients: 
 Results are reported in Table 16 for the original scale of data since no transformations 
were required before analysis. The data do not detect any significant differences between stage 
of disease and control for LC patients. All P-values are large and all intervals cover zero. 
 
Table 16: Estimates of contrasts comparing stage of disease and controls on the original scale. 
Column descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
  I   minus C -0.1268 0.8600 -1.9561 1.7025 
 II   minus C  0.0492 0.8867 -0.8296 0.9280 
III   minus C  0.3210 0.3862 -0.6146 1.2565 
 
7. Analysis of MMP7 Data 
7A) BC Patients versus Control 
 Diagnostics suggested a natural logarithm transformation of the MMP7 measurements. 
The third measurement for subject NS2011-027B (Stage III BC patient) and the third 
measurement for subject NS2011-010C (control patient) were identified as outliers and removed 
from the analysis. Age was not significant (P = 0.621) in the model. A total of 94 observations 
were analyzed.  
Results and Discussion of MMP7 for BC Patients: 
 Results are reported in Table 17 on the log-scale and Table 18 for the original scale of 
data. Estimates in Table 17 are estimates of multiplicative effects. Confidence intervals in Table 
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16 show significance if they do not cover zero after the Bonerroni adjustment for five 
simultaneous estimates. There is some evidence that mean log-MMP7 for stage II is different 
from control. The fact that P-values remain small for comparisons of stage III and IV with the 
controls suggest that the MMP7 measurements do distinguish between a stage of disease and 
control for BC patients. The lack of significance could be due to the smaller sample sizes and the 
fact that this particular measurement seemed to contain more noise than others. Interval estimates 
on the original scale are shown in Table 18. Intervals not covering 1 are showing significance.  
 
Table 17: Estimates of contrasts comparing stage of disease and controls on the log-scale. Column 
descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
0   minus C -0.1059 0.6226 -0.6896 0.4777 
I   minus C  0.3818 0.0827 -0.2018 0.9655 
II  minus C  0.5076 0.0082  0.0144 1.0009 
III minus C  0.2797 0.0535 -0.1024 0.6618 
IV  minus C  0.2880 0.0375 -0.0754 0.6515 
Table 18: Similar to Table 17 but on the original scale. Only interval estimates are given. Estimates 
are on a multiplicative scale. 
Label Estimate Lower Upper 
0   minus C 0.8995 0.5018 1.6124 
I   minus C 1.4650 0.8172 2.6261 
II  minus C 1.6613 1.0145 2.7207 
III minus C 1.3228 0.9027 1.9383 
IV  minus C 1.3338 0.9274 1.9184 
 
7B) LC Patients versus Control 
 A natural logarithm transformation of the MMP7 measurements was again used here. The 
third measurement for subject NS2011-010C (control patient) was an outlier as before and 
removed from the analysis. Stage II LC subject NS2011-019L produced some outlying residuals 
in the model, but they were not deemed extreme enough to warrant removal of those 
observations from the analysis. Age was not significant (P = 0.963) in the model. A total of 71 
observations were analyzed.  
Results and Discussion of MMP7 for LC Patients: 
Results are reported in Table 19 for the log-scale and in Table 20 for the original scale. The data 
show some evidence of significant differences between stage of disease and control for LC 
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patients. In particular, levels of MMP7 appear to be elevated in LC patients versus controls. 
Table 20 shows that estimated average levels of MMP7 in LC patients is 1.7 times larger than 
controls in stage I, 1.1 times larger than controls in stage II, and 1.4 times larger than controls in 
stage III. The inconsistency of statistical significance across the three stages could be due to the 
small sample size. A larger sample size may help to resolve whether the inconsistency is real or 
an artifact of low power.  
 
Table 19: Estimates of contrasts comparing stage of disease and controls on the log-scale. Column 
descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
I   minus C 0.5294 0.0068  0.0698 0.9891 
II  minus C 0.1087 0.2175 -0.1121 0.3295 
III minus C 0.3089 0.0025  0.0739 0.5440 
Table 20: Similar to Table 19 but on the original scale. Only interval estimates are given. Estimates 
are on a multiplicative scale. 
Label Estimate Lower Upper 
I   minus C 1.6979 1.0721 2.6891 
II  minus C 1.1148 0.8939 1.3904 
III minus C 1.3620 1.0766 1.7230 
 
8. Analysis of MMP9 Data 
8A) BC Patients versus Control 
 Measurements of MMP9 were very large in scale. To make them more manageable 
numerically, they were divided by 100,000. The resulting range for MMP9 values after this 
scaling was 40.17 to 166.79. No transformation was indicated and no outliers were seen in 
diagnostic plots of residuals. It was noted that all measurements for subjects NS2011-003B 
(stage IV BC patient) and NS2011-011B (stage III BC patient) were unusually small compared 
to other measurements for these stages of disease. These patients were left in the analysis. 
Another note was that MMP9 measurements for BC patients seemed to systematically increase 
from the first patient in the data set to the 20
th
 BC patient. In particular, a change was seen after 
the 7
th
 patient in the data set. Some of the increases in MMP9 values after this patient were due 
to later stages in disease tending to occur more frequently in the observations 8 to 20 versus 
observations 1 to 7. But it is not clear that this was the only reason that these increases were 
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seen. If these measurements were carried out in sequence, it might suggest some condition in the 
laboratory process that is creating dependence in measurements. If this is the case, the validity of 
results that follow could be questionable. Age was not significant in the model (P = 0.456). 
Results and Discussion of MMP9 for BC Patients: 
 Results are reported in Table 21 for the original scale of data after division by 100,000. 
No nonlinear logarithmic transformation was needed. The data suggest significant differences 
between stage  III and IV of disease versus control. There is some evidence that the mean MMP9 
values in BC patients begin to depart significantly from the control condition beginning at stage 
II. For example, the mean MMP9 level for a stage II BC patient is estimated to be 45.8 units 
higher than control. To return to the original scale of the MMP9 values, all estimates in Table 21 
would need to be multiplied by 100,000.  
 
Table 21: Estimates of contrasts comparing stage of disease and controls on the original scale but 
after division by 100,000. Column descriptions are those as described for Table 1. 
Label Estimate P-value  Lower        Upper 
0   minus C -6.2123 0.7752 -65.2869 52.8624 
I   minus C  5.5644 0.7981 -53.5103 64.6390 
II  minus C 45.7877 0.0173  -4.1395 95.7149 
III minus C 72.0707 <.0001  33.3973 110.740 
IV  minus C 69.2386 <.0001  32.4528 106.020 
 
8B) LC Patients versus Control 
 This set of data was different from others in that MMP9 measurements for LC patients 
were of a scale lower than control patients. Summary measures of location for MMP9 
measurements in control patients were 5.6 to 9 times larger than those of LC patients. The 
standard deviation of MMP9 measurements was 3.5 times large in control patients than LC 
patients. Outlying observations were noted and due to the larger variance in MMP9 values in 
control patients, but there was no single observation that stood out, so all data were left in the 
analysis. As in the BC measurements it was noted that measures of MMP9 in LC patients 
seemed to be systematically higher in the observations appearing later in the data set versus those 
that appeared earlier. Again, if measurements of MMP9 for LC patients were taken in sequence, 
it is possible some dependence was introduced in the laboratory process of obtaining 
measurements. The substantial gap in MMP9 measurements between control and LC patients, as 
well as the increased variance of measurements in controls made it difficult to transform data so 
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that model diagnostics looked adequate for linear modeling. Nevertheless, a natural logarithm 
transformation was applied to MMP9 values and used as the response variable. Age was not 
significant (P = 0.703). A total 72 observations were analyzed.  
Results and Discussion of MMP9 for LC Patients: 
 Results are reported in Table 22 for the log-scale and Table 23 for the original scale of 
data. The data suggest very significant differences between stage of disease and control for LC 
patients. All P-values are small and all intervals fall below zero in Table 22 and below 1 in Table 
23. This indicates that mean levels of MMP9 are smaller in LC patients versus controls for all 
three stages available in the data (stages I, II, and III). As illustration of Table 23, mean MMP9 
values in both stage II and III LC patients is estimated to be about 15% of the mean value in 
control patients. With 95% confidence, this percentage could be as small as about 10% and as 
large as 22%.  
 
Table 22: Estimates of contrasts comparing stage of disease and controls on the log-scale. Column 
descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
I   minus C -2.7396 <.0001 -3.4769 -2.0023 
II  minus C -1.8566 <.0001 -2.2108 -1.5024 
III minus C -1.8862 <.0001 -2.2633 -1.5091 
Table 23: Similar to Table 22 but on the original scale. Only interval estimates are given. Estimates 
are on a multiplicative scale. 
Label Estimate Lower Upper 
I   minus C 0.0646 0.0309 0.1351 
II  minus C 0.1562 0.1096 0.2226 
III minus C 0.1516 0.1040 0.2211 
 
9. Analysis of MMP 13 Data 
9A) BC Patients versus Control 
 A natural logarithm transformation was suggested for the MMP 13 outcome variable. 
Age was not significant in the model and no outlying residuals were noted. It was noted that the 
predicted subject effects for BC patients NS2011-011B (stage III) and NS2011-020B (stage IV) 
were unusually large due to unusually large measurements of MMP 13 for these two subjects. 
Since the residuals for these observations were not unusual, these observations were left in the 
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following analyses. However, a second analysis was conducted for comparison purposes that 
omitted the three measurements for these two subjects. A total 96 observations were analyzed in 
results that follow. 
Results and Discussion of MMP 13 for BC Patients: 
Table 24 shows results on the log-scale and Table 25 shows results on the original scale. There 
were no significant differences seen for any stage in BC patients versus controls. As a second 
check, the two BC patients mentioned above were omitted from another analysis. A difference 
between stage I versus control was seen, but this difference was not apparent in any other stage 
versus the control condition. 
 
Table 24: Estimates of contrasts comparing stage of disease and controls on the log-scale. Column 
descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
0   minus C -0.2574 0.4612 -1.2027 0.6878 
I   minus C  0.6003 0.0916 -0.3450 1.5455 
II  minus C -0.2223 0.4516 -1.0212 0.5765 
III minus C  0.0402 0.8599 -0.5786 0.6590 
IV  minus C -0.1093 0.6145 -0.6979 0.4793 
Table 25: Similar to Table 24 but on the original scale. Only interval estimates are given. Estimates 
are on a multiplicative scale. 
Label Estimate Lower Upper 
0   minus C 0.7730 0.3004 1.9893 
I   minus C 1.8226 0.7083 4.6902 
II  minus C 0.8007 0.3602 1.7798 
III minus C 1.0410 0.5607 1.9328 
IV  minus C 0.8964 0.4976 1.6149 
 
9B) LC Patients versus Control 
 A natural logarithm transformation was done for the MMP 13 response variable. Subject 
code NS2011-019L (LC Stage III, patient L4) had unusually large values of MMP13. After 
transformation, the predicted subject effect for this patient was large but not extreme. Moreover, 
this observation did not produce outliers in residuals from the model. So data for this patient was 
left in the analyses that follow. Age was not significant in the model (P = 0.878).   
Results and Discussion of MMP 13 for LC Patients: 
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 Table 26 shows results on the log-scale and Table 27 shows results on the original scale. 
There were no significant differences seen for any stage in LC patients versus controls. 
 
Table 26: Estimates of contrasts comparing stage of disease and controls on the log-scale. Column 
descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
I   minus C  0.1063 0.7434 -0.7195 0.9320 
II  minus C -0.1142 0.4661 -0.5109 0.2825 
III minus C -0.0778 0.6399 -0.5001 0.3440 
Table 27: Similar to Table 26 but on the original scale. Only interval estimates are given. Estimates 
are on a multiplicative scale. 
Label Estimate Lower Upper 
I   minus C 1.1121 0.4869 2.5403 
II  minus C 0.8921 0.5999 1.3266 
III minus C 0.9252 0.6064 1.4115 
 
10. Analysis of uPA Data 
10A) BC Patients versus Control 
 A natural logarithm of uPA was suggested by diagnostic plots. The first measurement for 
subject NS2011-008C (control subject) was an outlier and removed from the analysis. There 
were measurements for subject NS2011-037B (stage III BC patient) that were boarder line 
outliers, but these observations were left in the analyses that follow. Age was marginally 
significant (P = 0.027) and, so, was included as a covariate in this model. An Age-Staging 
interaction term was not significant. A total of 95 observations were analyzed.  
Results and Discussion of uPA for BC Patients: 
 Table 28 shows results on the log-scale and Table 29 shows results on the original scale. 
Mean uPA levels are estimated to be significantly lower in stage II, III, and IV versus control 
patients. Table 29 indicates that for stage II BC patients, the mean uPA level is estimated to be 
about 14% that of the control condition. The uncertainty in this value ranges from about 3% to 
63% at 95% confidence. The uncertainty range is wide due, most likely, to small sample sizes. 
The effect of Age in the model indicated that older patients tended to have slightly higher levels 
of uPA.  
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Table 28: Estimates of contrasts comparing stage of disease and controls on the log-scale for uPA 
measurements in BC patients. Column descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
0   minus C  0.5279 0.4133 -1.2159  2.2717 
I   minus C -1.2101 0.0991 -3.1610  0.7407 
II  minus C -1.9529 0.0011 -3.4443 -0.4614 
III minus C -1.5402 0.0020 -2.7944 -0.2860 
IV  minus C -1.5160 0.0017 -2.7277 -0.3042 
Table 29: Estimates of contrasts comparing stage of disease and controls on the original scale for 
uPA measurements in BC patients on the original scale. Estimated effects are multiplicative. 
Label Estimate Lower Upper 
0   minus C 1.6953 0.2964 9.6969 
I   minus C 0.2982 0.0424 2.0978 
II  minus C 0.1419 0.0319 0.6304 
III minus C 0.2143 0.0611 0.7513 
IV  minus C 0.2196 0.0654 0.7378 
 
10B) LC Patients versus Control 
 A natural logarithm of uPA was again used as the response variable, and the first 
observation for subject NS2011-008C (control subject) was an outlier and removed from the 
analysis as it was for the analysis of data for BC subjects. Residuals from the model were slightly 
heavy tailed even after the logarithm transformation. This is not likely to influence overall 
conclusions. A larger sample size would help determine an optimal model to use for this 
analysis. There was no one patient that contributed to the heavy tailed distribution of residuals. 
Age was not significant in this model (P = 0.645) and was not used as a covariate.  
Results and Discussion of uPA for LC Patients: 
 Table 30 shows results on the log-scale and Table 31 shows results on the original scale. 
There were no significant differences seen for any stage in LC patients versus controls. 
 
Table 30: Estimates of contrasts comparing stage of disease and controls on the log-scale for uPA 
for LC patients. Column descriptions are those as described for Table 1. 
Label Estimate P-value Lower Upper 
I   minus C -0.6060 0.5285 -3.0432 1.8313 
II  minus C -0.6915 0.1417 -1.8624 0.4793 
III minus C -0.9500 0.0616 -2.1964 0.2964 
 
   181 
 
Table 31: Estimates of contrasts comparing stage of disease and controls on the original scale for 
uPA measurements in LC patients on the original scale. Estimated effects are multiplicative. 
Label Estimate Lower Upper 
I   minus C 0.5455 0.0476 6.2475 
II  minus C 0.5008 0.1552 1.6156 
III minus C 0.3867 0.1111 1.3457 
 
 
 
 
 
 
